<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2705257473
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DESCOVY 200MG/10MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        EMTRICITABINE,TENOFOVIR ALAFENAMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200,11.2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1711.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PATHEON INC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PATHEON INC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gilead Sciences International Ltd 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AR 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Descovy contains two active substances:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>emtricitabine</strong><strong>,</strong> an antiretroviral medicine of a type known as a nucleoside reverse transcriptase inhibitor (NRTI)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>tenofovir alafenamide</strong><strong>,</strong> an antiretroviral medicine of a type known as a nucleotide reverse transcriptase inhibitor (NtRTI)</p><p>Descovy blocks the action of the reverse transcriptase enzyme, which is essential for the virus to multiply.&nbsp; Descovy, therefore, reduces the amount of HIV in your body.</p><p>Descovy in combination with other medicines is for the treatment of human immunodeficiency virus&nbsp;1 (HIV‑1) infection in adults and adolescents 12&nbsp;years of age and older, who weigh at least 35&nbsp;kg.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Descovy</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are allergic</strong><strong> to emtricitabine, tenofovir alafenamide</strong> or any of the other ingredients of this medicine (listed in section&nbsp;6 of this leaflet).</p><p><strong>Warnings and precautions</strong></p><p>You must remain under the care of your doctor while taking Descovy.</p><p>You can still pass on HIV when taking this medicine, although the risk is lowered by effective antiretroviral therapy. &nbsp;Discuss with your doctor the precautions needed to avoid infecting other people. &nbsp;This medicine is not a cure for HIV&nbsp;infection. &nbsp;While taking Descovy you may still develop infections or other illnesses associated with HIV&nbsp;infection.</p><p><strong>Talk to your doctor before taking Descovy:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have liver problems or have suffered liver disease, including hepatitis.</strong> &nbsp;Patients with liver disease including chronic hepatitis&nbsp;B or&nbsp;C, who are treated with antiretrovirals, have a higher risk of severe and potentially fatal liver complications. &nbsp;If you have hepatitis&nbsp;B infection, your doctor will carefully consider the best treatment regimen for you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have hepatitis&nbsp;B infection</strong>, liver problems may become worse after you stop taking Descovy. &nbsp;Do not stop taking Descovy without talking to your doctor: see section&nbsp;3, <em>Do not stop taking Descovy</em>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may choose to not prescribe Descovy to you if your virus has a certain resistance mutation, as Descovy may not be able to reduce the amount of HIV in your body as effectively.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have had kidney disease or if tests have shown problems with your kidneys.</strong>&nbsp; Your doctor may order blood tests to monitor how your kidneys work when starting and during treatment with Descovy.</p><p><strong>While you are taking Descovy</strong></p><p>Once you start taking Descovy, look out for:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Signs of inflammation or infection</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Joint pain, stiffness</strong> or <strong>bone problems</strong></p><p><strong>If you notice any of these symptoms, tell your doctor immediately.</strong> &nbsp;For more information see section&nbsp;4, <em>Possible side effects</em>.</p><p>Although kidney problems have not been observed with Descovy, there is a possibility that you may experience kidney problems when taking Descovy over a long period of time (<em>see Warning and precautions).</em></p><p><strong>Children and adolescents</strong></p><p><strong>Do not give this medicine to children</strong> aged 11&nbsp;years or under, or weighing less than 35&nbsp;kg. &nbsp;The use of Descovy in children aged 11&nbsp;years or under has not yet been studied.</p><p><strong>Other medicines and Descovy</strong></p><p><strong>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</strong> &nbsp;Descovy may interact with other medicines. &nbsp;As a result, the amounts of Descovy or other medicines in your blood may change. &nbsp;This may stop your medicines from working properly, or may make any side effects worse. &nbsp;In some cases, your doctor may need to adjust your dose or check your blood levels.</p><p><strong>Medicines used in treating hepatitis&nbsp;B infection:</strong></p><p>You should not take Descovy with medicines containing:</p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tenofovir alafenamide</strong></p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tenofovir disoproxil</strong></p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lamivudine</strong></p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adefovir dipivoxil</strong></p><p><strong>Tell your doctor</strong> if you are taking any of these medicines.</p><p><strong>Other types of medicine:</strong></p><p>Talk to your doctor if you are taking:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>antibiotics,</strong> used to treat bacterial infections including tuberculosis, containing:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifabutin, rifampicin, and rifapentine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>antiviral medicines used to treat HIV:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; emtricitabine and tipranavir</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>anticonvulsants,</strong> used to treat epilepsy, such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine, oxcarbazepine, phenobarbital and phenytoin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>herbal remedies</strong> used to treat depression and anxiety containing:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St.&nbsp;John&rsquo;s wort (<em>Hypericum perforatum</em>)</p><p><strong>Tell your doctor if you are taking these or any other medicines. </strong>&nbsp;Do not stop your treatment without contacting your doctor.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor immediately if you become pregnant and ask about the potential benefits and risks of your antireytoviral therapy to you and your child.</p><p>If you have taken Descovy during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child.&nbsp; In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.</p><p><strong>Do not breast-feed during treatment with Descovy.</strong> &nbsp;This is because one of the active substances in this medicine passes into breast milk. &nbsp;It is recommended that you do not breast-feed to avoid passing the virus to the baby through breast milk.</p><p><strong>Driving and using machines</strong></p><p>Descovy can cause dizziness. &nbsp;If you feel dizzy when taking Descovy, do not drive and do not use any tools or machines.</p><p><strong>Descovy contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium‑free&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. &nbsp;Check with your doctor or pharmacist if you are not sure.</p><p><strong>The recommended dose is:</strong></p><p><strong>Adults:</strong> one tablet each day, with or without food</p><p><strong>Adolescents 12&nbsp;years of age and older, who weigh at least 35&nbsp;kg: </strong>one tablet each day with or without food</p><p>It is recommended not to chew or crush the tablet due to the bitter taste.</p><p>If you have difficulty swallowing the tablet whole, you can split it in half.&nbsp; Take both halves of the tablet one after the other to get the full dose.&nbsp; Do not store the split tablet.</p><p><strong>Always take the dose recommended by your doctor.</strong> &nbsp;This is to make sure that your medicine is fully effective, and to reduce the risk of developing resistance to the treatment. &nbsp;Do not change the dose unless your doctor tells you to.</p><p><strong>If you are on dialysis,</strong> take your daily dose of Descovy following completion of dialysis.</p><p><strong>If you take more Descovy than you should</strong></p><p>If you take more than the recommended dose of Descovy you may be at higher risk of side effects of this medicine (see section&nbsp;4, <em>Possible side effects</em>).</p><p>Contact your doctor or nearest emergency department immediately for advice. &nbsp;Keep the tablet bottle with you so that you can show what you have taken.</p><p><strong>If you forget to take Descovy</strong></p><p>It is important not to miss a dose of Descovy.</p><p>If you do miss a dose:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you notice </strong><strong>within 18&nbsp;hours</strong> of the time you usually take Descovy, you must take the tablet as soon as possible. &nbsp;Then take the next dose as usual.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you notice </strong><strong>18&nbsp;hours or more</strong> after the time you usually take Descovy, then do not take the missed dose. &nbsp;Wait and take the next dose at your usual time.</p><p><strong>If you vomit less than 1&nbsp;hour after taking Descovy,</strong> take another tablet.</p><p><strong>Do not stop taking Descovy</strong></p><p><strong>Do not stop taking Descovy without talking to your doctor. &nbsp;</strong>Stopping Descovy can seriously affect how well future treatment works. &nbsp;If Descovy is stopped for any reason, speak to your doctor before you restart taking Descovy tablets.</p><p><strong>When your supply of Descovy starts to run low, </strong>get more from your doctor or pharmacist. &nbsp;This is very important because the amount of virus may start to increase if the medicine is stopped for even a few days. &nbsp;The disease may then become harder to treat.</p><p><strong>If you have both HIV&nbsp;infection and hepatitis&nbsp;B,</strong> it is very important not to stop taking Descovy without talking to your doctor first. &nbsp;You may require blood tests for several months after stopping treatment. &nbsp;In some patients with advanced liver disease or cirrhosis, stopping treatment may lead to worsening of hepatitis, which may be life-threatening.</p><p><strong>Tell your doctor immediately </strong>about new or unusual symptoms after you stop treatment, particularly symptoms you associate with hepatitis&nbsp;B infection.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Possible serious side effects: tell a doctor immediately</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Any signs of inflammation or infection.</strong> &nbsp;In some patients with advanced HIV&nbsp;infection (AIDS) and who have had opportunistic infections in the past (infections that occur in people with a weak immune system), signs and symptoms of inflammation from previous infections may occur soon after antiretroviral treatment is started. &nbsp;It is thought that these symptoms are due to an improvement in the body&rsquo;s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Autoimmune disorders</strong> (the immune system attacks healthy body tissue), may also occur after you start taking medicines for HIV&nbsp;infection. &nbsp;Autoimmune disorders may occur many months after the start of treatment. &nbsp;Look out for any symptoms of infection or other symptoms such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness beginning in the hands and feet and moving up towards the trunk of the body</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; palpitations, tremor or hyperactivity</p><p><strong>&nbsp;If you notice the side effects described above, tell your doctor immediately.</strong></p><p><strong>Very common side effects</strong></p><p>(<em>may affect more than 1 in 10&nbsp;people</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (<em>nausea</em>)</p><p><strong>Common side effects</strong></p><p>(<em>may affect up to 1 in 10&nbsp;people</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal dreams</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wind (<em>flatulence</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness (<em>fatigue</em>)</p><p><strong>Uncommon side effects</strong></p><p>(<em>may affect up to 1 in 100&nbsp;people</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low red blood cell count (<em>anaemia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems with digestion resulting in discomfort after meals (<em>dyspepsia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, tongue or throat (<em>angioedema</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching (<em>pruritus</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives<em> (urticaria)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain<em> (arthralgia)</em></p><p><strong>If any of the side effects get serious tell your doctor.</strong></p><p><strong>Other effects that may be seen during HIV&nbsp;treatment</strong></p><p>The frequency of the following side effects is not known (frequency cannot be estimated from the available data).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Bone problems.</strong> &nbsp;Some patients taking combination antiretroviral medicines such as Descovy may develop a bone disease called <em>osteonecrosis</em> (death of bone tissue caused by loss of blood supply to the bone). &nbsp;Taking this type of medicine for a long time, taking corticosteroids, drinking alcohol, having a very weak immune system, and being overweight, may be some of the many risk factors for developing this disease. &nbsp;Signs of osteonecrosis are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint stiffness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint aches and pains (especially of the hip, knee and shoulder)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty with movement</p><p><strong>If you notice any of these symptoms tell your doctor.</strong></p><p>During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose.&nbsp; This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves.&nbsp; Your doctor will test for these changes.</p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist. You can also report side effects directly via the national reporting system.</p><p>&nbsp;</p><p>By reporting side effects you can help provide more information on the safety of this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and bottle after &ldquo;EXP&rdquo;. &nbsp;The expiry date refers to the last day of that month.</p><p>Store in the original package in order to protect from moisture. &nbsp;Keep the bottle tightly closed.</p><p>Do not throw away any medicines via wastewater or household waste. &nbsp;Ask your pharmacist how to throw away medicines you no longer use. &nbsp;These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The active substances are</strong> emtricitabine and tenofovir alafenamide. &nbsp;Each Descovy film‑coated tablet contains 200&nbsp;mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 10&nbsp;mg of tenofovir alafenamide.</p><p><strong>The other ingredients are</strong></p><p><em>Tablet core:</em></p><p>Microcrystalline cellulose, croscarmellose sodium, magnesium stearate.</p><p><em>Film</em><em>‑</em><em>coating:</em></p><p>Polyvinyl alcohol, titanium dioxide, macrogol&nbsp;3350, talc, iron oxide black (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Descovy film coated tablets are grey, rectangular shaped tablets, debossed on one side with “GSI” and the number “210” on the other side of the tablet.
	Descovy comes in bottles of 30 tablets (with a silica gel desiccant that must be kept in the bottle to help protect your tablets).  The silica gel desiccant is contained in a separate sachet or canister and should not be swallowed.
	
	The following pack sizes are available: outer cartons containing 1 bottle of 30 film coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder, Packaging and Final Batch Release Site:</strong></p><p>Gilead Sciences Ireland UC</p><p>IDA Business &amp; Technology Park</p><p>Carrigtohill</p><p>County Cork</p><p>Ireland</p><p>Tel: +353 (0) 21 483 5500</p><p>Fax: +353 (0) 21 483 5518</p><p>E mail: csafety@gilead.com</p><p><strong>Bulk Manufacturer and Packaging Site</strong></p><p>Patheon Inc.</p><p>Toronto Regional Operations</p><p>2100 Syntex Court</p><p>Mississauga</p><p>Ontario L5N 7K9</p><p>Canada</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي ديسكوفي على مادتين فعالتين هما:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إميتريسيتاباين</strong>، دواء مضاد للفيروس القهقري من نوع يعرف باسم مثبط نيوكليوسايد للمنتسخة العكسية (NRTI)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp; تينوفوفير ألافينامايد، </strong>دواء مضاد للفيروس القهقري من نوع يعرف باسم مثبط نيوكليوتايد للمنتسخة العكسية (NtRTI)</p><p dir="RTL">يغلق ديسكوفي عمل إنزيم المنتسخة العكسية، الذي هو ضروري لتكاثر الفيروس. وبهذا فإن ديسكوفي يخفض كمية فيروس العوز المناعي البشري في جسمك.</p><p dir="RTL">تستعمل توليفة ديسكوفي مع أدوية أخرى لعلاج <strong>عدوى فيروس العوز المناعي البشري&nbsp;1 (HIV 1)</strong> في البالغين والمراهقين ممن لديهم 12 سنة من العمر فأكبر، والذين وزنهم 35&nbsp;كغم على الأقل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول ديسكوفي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp; إذا كان لديك تحسس من إميتريسيتاباين أو تينوفوفير ألافينامايد</strong> أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6 من هذه النشرة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">يجب أن تبقى تحت رعاية طبيبك أثناء تناولك ديسكوفي.</p><p dir="RTL"><strong>لا يزال بإمكانك نقل فيروس عوز المناعة البشرية</strong> عند تناول هذا الدواء، على الرغم من أن المخاطر منخفضة عن طريق العلاج الفعال المضاد للفيروسات القهقرية. ناقش مع طبيبك الاحتياطات اللازمة لتجنب إصابة أشخاص آخرين. هذا الدواء ليس علاجًا لعدوى فيروس عوز المناعة البشرية. وأثناء تناول ديسكوفي فإنه ما زال من المحتمل أن تتطور عندك عدوى أو أمراض أخرى مرتبطة بفيروس عوز المناعة البشرية.</p><p dir="RTL"><strong>تحدث مع طبيبك قبل تناول ديسكوفي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp; إذا كان لديك مشاكل في الكبد أو عانيت من أمراض الكبد</strong>، بما في ذلك التهاب الكبد. المرضى الذين يعانون من أمراض الكبد بما في ذلك التهاب الكبد المزمن&nbsp;B أو&nbsp;C، والذين يتم علاجهم باستخدام مضادات الفيروسات القهقرية، يكونون أكثر عرضة لمضاعفات كبدية خطيرة وقاتلة. إذا كان لديك التهاب الكبد B، فسوف ينظر طبيبك بعناية في أفضل نظام علاجي لك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp; إذا كان لديك عدوى التهاب الكبد&nbsp;B </strong>فإن مشاكل الكبد قد تصبح أسوأ بعد التوقف عن تناول ديسكوفي. لا تتوقف عن تناول ديسكوفي دون التحدث مع طبيبك: انظر القسم 3، <em>لا تتوقف عن تناول ديسكوفي</em>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد لا يصف لك طبيبك ديسكوفي في حال إذا كان الفيروس لديك يتمتع بطفرة مقاومة معينة، بحيث قد لا يكون ديسكوفي قادرًا على تقليل كمية فيروس نقص المناعة البشرية في جسمك بشكل فعال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp;&nbsp; إذا كان لديك أمراض الكلى أو أظهرت الفحوصات مشاكل في كليتيك</strong>. قد يطلب طبيبك إجراء اختبارات الدم لمراقبة كيفية عمل كليتيك عند بدء العلاج وأثناء العلاج بديسكوفي.</p><p dir="RTL"><strong>أثناء تناولك ديسكوفي</strong></p><p dir="RTL">بمجرد البدء في تناول ديسكوفي، انتبه لما يلي:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات التهاب أو عدوى</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل، تصلب أو مشاكل في العظام</strong></p><p dir="RTL"><strong>إذا لاحظت أياً من هذه الأعراض، فأخبر طبيبك فوراً. </strong>لمزيد من المعلومات انظر القسم&nbsp;4، <em>الأعراض الجانبية المحتملة</em>.</p><p dir="RTL">على الرغم من عدم ملاحظة مشاكل في الكلى أثناء تناول ديسكوفي، إلا أن هناك احتمالاً أن تواجه مشاكل في الكلى عند تناول ديسكوفي على مدى فترة طويلة من الزمن (<em>انظر التحذيرات والاحتياطات).</em></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL"><strong>لا تعطِ هذا الدواء للأطفال </strong>الذين أعمارهم&nbsp;11 سنة أو أقل، أو وزنهم أقل من&nbsp;35 كلغم. لم يتم بعد دراسة استعمال ديسكوفي في الأطفال الذين أعمارهم&nbsp;11 سنة أو أقل.</p><p dir="RTL"><strong>الأدوية الأخرى وديسكوفي</strong></p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو قد تناولت مؤخراً أو قد تتناول أي أدوية أخرى.</strong> قد يتفاعل ديسكوفي مع الأدوية الأخرى. ونتيجة لذلك، قد تتغير كمية ديسكوفي أو غيرها من الأدوية في دمك. وهذا قد يوقف عمل هذا الدواء بشكل صحيح، أو قد يجعل الأعراض الجانبية أسوأ. في بعض الحالات، قد يحتاج طبيبك لتنظيم الجرعة أو فحص مستويات دمك.</p><p dir="RTL"><strong>الأدوية المستعملة في علاج التهاب الكبد&nbsp;B:</strong></p><p dir="RTL">يجب ألا تتناول ديسكوفي مع الأدوية التي تحتوي على:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تينوفوفير ألافيناميد</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تينوفوفير دايس</strong><strong>و</strong><strong>بروكسيل</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>لاميفودين</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>أديفوفير دايبيفوكسيل</strong></p><p dir="RTL"><strong>أخبر طبيبك </strong>إذا كنت تتناول أياً من هذه الأدوية.</p><p dir="RTL"><strong>أنواع أخرى من الأدوية:</strong></p><p dir="RTL">تحدث مع طبيبك إذا كنت تتناول:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المضادات الحيوية، </strong>وتستخدم لعلاج الالتهابات البكتيرية بما في ذلك السل، والتي تحتوي على:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفابيوتين، ريفامبيسين، و ريفابينتين</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الأدوية المضادة للفيروسات المستخدمة في علاج فيروس عوز المناعة البشرية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إميتريسيتاباين و تيبرانافير</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>مضادات الاختلاج، </strong>وتستخدم لعلاج الصرع، مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين، اوكسكاربازيبين، فينوباربيتال وفينيتوين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>العلاجات العشبية </strong>المستخدمة في علاج الاكتئاب والقلق التي تحتوي على:</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>نبتة سانت جون<strong> </strong>(<em>Hypericum perforatum</em>)</p><p dir="RTL"><strong>أخبر طبيبك إذا كنت تتناول هذه الأدوية أو أي أدوية أخرى.</strong> لا تتوقف عن العلاج دون الاتصال بطبيبك.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حاملًا أو ترضعين طفلك طبيعيًا، أو تعتقدين بأنك قد تكونين حاملًا أو تخططين لإنجاب طفل، فاسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبري طبيبك على الفور إذا أصبحتِ حاملًا واسألي عن الفوائد والمخاطر المحتملة للعلاج بمضادات الفيروسات الرجعية لك ولطفلك.</p><p dir="RTL">إذا كنتِ قد تناولتِ ديسكوفي أثناء حملكِ، فقد يطلب منكِ طبيبكِ إجراء اختبارات دم منتظمة وبعض الاختبارات التشخيصية الأخرى لمراقبة تطور طفلكِ. بالنسبة للأطفال الذين تناولت أمهاتهم مثبطات نيوكليوسايد للمنتسخة العكسية أثناء الحمل (NRTI)، كانت الفائدة العائدة من الحماية من فيروس عوز المناعة البشرية تفوق مخاطر الأعراض الجانبية.</p><p dir="RTL"><strong>لا ترضعي طفلك طبيعياً أثناء العلاج بديسكوفي.</strong> ذلك لأن إحدى المادتين الفعالتين في هذا الدواء تمر في حليب الثدي. لهذا من المستحسن أن لا ترضعي طفلك طبيعياً لتجنب انتقال الفيروس إلى الطفل عن طريق حليب الثدي.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يمكن أن يسبب ديسكوفي الدوخة. إذا كنت تشعر بالدوار عند تناول ديسكوفي، فلا تقُد ولا تستخدم أي أدوات أو آلات.</p><p dir="RTL"><strong>يحتوي ديسكوفي على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول من الصوديوم (23 ملغم) لكل قرص وهذا يعني بشكل أساسي بأنه &quot;خالٍ من الصوديوم&quot;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائمًا تناول هذا الدواء تمامًاً كما يخبرك&nbsp; طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL"><strong>الجرعة الموصى بها هي:</strong></p><p dir="RTL"><strong>البالغون:</strong> قرص واحد كل يوم، مع أو بدون طعام</p><p dir="RTL"><strong>المراهقون&nbsp;12 سنة من العمر فأكبر، الذين أوزانهم&nbsp;35 كغم على الأقل:</strong> قرص واحد كل يوم مع أو بدون طعام</p><p dir="RTL">يوصى بعدم مضغ أو سحق القرص بسبب الطعم المر.</p><p dir="RTL">إذا كنت تواجه صعوبة في بلع القرص بالكامل، فيمكنك تقسيمه إلى نصفين. خذ نصفي القرص واحدًا تلو الآخر لإكمال الجرعة الكاملة. لا تقم بتخزين القرص المقسم.</p><p dir="RTL"><strong>دائماً تناول الجرعة الموصى بها من قبل طبيبك.</strong> وهذا للتأكد من أن الدواء فعال تماماً، ومن أجل تقليل خطر تطور مقاومة للعلاج. لا&nbsp;تغير الجرعة ما لم يخبرك طبيبك بذلك.</p><p dir="RTL"><strong>إذا كنت تُعالج بالغسيل الكلوي</strong>، فتناول جرعتك اليومية من ديسكوفي عقب اكتمال الغسيل الكلوي.</p><p dir="RTL"><strong>إذا كنت تناولت جرعة أكثر مما يجب من ديسكوفي</strong></p><p dir="RTL">إذا كنت تناولت جرعة أكثر من الموصى بها من ديسكوفي فإنك قد تكون أكثر عرضة للأعراض الجانبية لهذا الدواء (انظر القسم 4، <em>والأعراض الجانبية المحتملة</em>).</p><p dir="RTL">اتصل بطبيبك أو أقرب قسم طوارئ على الفور للحصول على المشورة. أبقِ قنينة الأقراص معك لكي تتمكن من عرض ما كنت قد&nbsp;تناولته.</p><p dir="RTL"><strong>إذا كنت قد نسيت أن تتناول ديسكوفي</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><p dir="RTL">من المهم عدم تفويت جرعة من ديسكوفي.</p><p dir="RTL">إذا كنت قد نسيت جرعة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong> إذا لاحظت ذلك في غضون 18 ساعة</strong> من الوقت الذي عادة ما تتناول فيه ديسكوفي، فيجب أن تتناول قرصاً في أقرب وقت ممكن. ثم تناول الجرعة التالية كالمعتاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong> إذا لاحظت ذلك بعد 18 ساعة أو أكثر </strong>من الوقت الذي عادة ما تتناول فيه ديسكوفي، فلا تتناول الجرعة المنسية. انتظر وتناول الجرعة التالية في الوقت المعتاد.</p><p dir="RTL"><strong>إذا تقيأت بعد أقل من ساعة واحدة من تناول ديسكوفي،</strong> فتناول قرصاً آخر.</p><p dir="RTL"><strong>لا تتوقف عن تناول ديسكوفي</strong></p><p dir="RTL"><strong>لا تتوقف عن تناول ديسكوفي دون التحدث مع طبيبك. </strong>وقف تناول ديسكوفي يمكن أن يؤثر تأثيرا خطيرا على مدى فعالية العلاج مستقبلاً. إذا تم إيقاف تناول ديسكوفي لأي سبب من الأسباب، فتحدث إلى طبيبك قبل إعادة تناول أقراص ديسكوفي.</p><p dir="RTL"><strong>عندما تبدأ كمية أقراص ديسكوفي التي عندك بالنقصان،</strong> فاحصل على كمية أخرى من طبيبك أو الصيدلي. وهذا أمر مهم جداً لأن كمية الفيروس قد تبدأ في الزيادة إذا تم إيقاف تناول الدواء حتى لو لأيام قليلة. وقد يصبح من الصعب علاج هذا المرض.</p><p dir="RTL"><strong>إذا كان لديك كل من عدوى فيروس عوز المناعة البشرية والتهاب الكبد&nbsp;B،</strong> فمن المهم جداً عدم التوقف عن تناول ديسكوفي دون التحدث مع طبيبك أولاً. قد تتطلب اختبارات للدم لعدة أشهر بعد التوقف عن العلاج. في بعض المرضى الذين يعانون من مرض الكبد المتقدم أو تليف الكبد، وقف العلاج قد يؤدي إلى تفاقم التهاب الكبد، والذي قد يكون مهدداً للحياة.</p><p dir="RTL"><strong>أخبر طبيبك فوراً </strong>عن الأعراض الجديدة أو غير العادية بعد توقفك عن العلاج، وخاصة الأعراض المصاحبة لعدوى التهاب الكبد&nbsp;B.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استعمال هذا الدواء، فاسأل طبيبك أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب أعراض جانبية، على الرغم من أنها لا تحصل عند الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الخطيرة المحتملة: أخبر الطبيب فوراً</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي علامات التهاب أو عدوى. </strong>في بعض المرضى الذين يعانون من إصابة متقدمة بفيروس عوز المناعة البشرية (الإيدز) والذين لديهم أمراض انتهازية في الماضي (العدوى التي تحدث في الأشخاص الذين يعانون من ضعف الجهاز المناعي)، وعلامات وأعراض التهاب من عدوى سابقة قد تحدث بعد وقت قصير من بدء العلاج المضاد للفيروسات القهقرية. ويعتقد أن&nbsp;هذه الأعراض هي نتيجة لحدوث تحسن في الاستجابة المناعية للجسم، مما يساعد الجسم على محاربة العدوى التي قد تكون موجودة مع عدم وجود أعراض واضحة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحدث أيضاً <strong>اضطرابات المناعة الذاتية </strong>(يهاجم الجهاز المناعي أنسجة الجسم الصحية)، بعد البدء بتناول الأدوية المضادة للإصابة بفيروس عوز المناعة البشرية. قد تحدث اضطرابات المناعة الذاتية بعد عدة أشهر من بدء العلاج. انتبه لأي أعراض للعدوى أو أعراض أخرى مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف يبدأ في اليدين والقدمين ويتحرك صعوداً نحو جذع الجسم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان أو رعاش أو فرط النشاط</p><p dir="RTL"><strong>&nbsp;إذا لاحظت أياً من الأعراض الجانبية المذكورة أعلاه، فأخبر طبيبك فوراً.</strong></p><p dir="RTL"><strong>الأعراض الجانبية الشائعة جداً</strong></p><p dir="RTL"><em>(قد تؤثر على أكثر من 1 في 10 أشخاص)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالتقيؤ (الغثيان)</p><p dir="RTL"><strong>الأعراض الجانبية الشائعة</strong></p><p dir="RTL"><em>(قد تؤثر على ما يصل إلى 1 في 10 أشخاص)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحلام غير طبيعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الرأس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقيؤ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الريح <em>(الغازات</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرهاق <em>(تعب)</em></p><p dir="RTL"><strong>الأعراض الجانبية غير الشائعة</strong></p><p dir="RTL"><em>(قد تؤثر على ما يصل إلى 1 في 100&nbsp;شخص)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء <em>(فقر الدم)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الهضم مما يؤدي إلى عدم الراحة بعد وجبات الطعام <em>(عسر الهضم)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه والشفتين واللسان أو الحلق <em>(وذمة وعائية)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة <em>(الحكة)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى <em>(الارتيكاريا)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل <em>(ألم مفصلي)</em></p><p dir="RTL"><strong>إذا أصبحت أي من الأعراض الجانبية خطيرة، فأخبر طبيبك.</strong></p><p dir="RTL"><strong>الأعراض الأخرى التي يمكن أن تشاهد أثناء علاج فيروس عوز المناعة البشرية</strong></p><p dir="RTL">إن تواتر الأعراض الجانبية التالية ليس معروفاً (لا يمكن تقدير التواتر من البيانات المتاحة).</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل العظام. </strong>بعض المرضى الذين يتناولون توليفة من الأدوية المضادة للفيروسات القهقرية مثل ديسكوفي قد تُظهر عندهم مرضاً في العظام يدعى <em>تنخر العظم</em> (موت أنسجة العظام التي يسببها فقدان تدفق الدم إلى العظام). إن تناول هذا النوع من الأدوية لفترة طويلة، مع الستيرويدات القشرية، وشرب الخمر، ووجود جهاز مناعة ضعيف جداً، وزيادة الوزن، قد تكون بعضا من كثير من عوامل خطر الإصابة بهذا المرض. علامات تنخر العظم هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب المفاصل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في المفاصل (وخاصة في الورك والركبة والكتف)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في الحركة</p><p dir="RTL"><strong>إذا لاحظت أياً من هذه الأعراض فأخبر طبيبك.</strong></p><p dir="RTL">خلال علاج فيروس عوز المناعة البشرية قد تكون هناك زيادة في الوزن وفي مستويات الدهون في الدم والغلوكوز. يرتبط هذا جزئياً باستعادة الصحة وأسلوب الحياة، وفي حالة دهون الدم، فهي أحياناً بسبب أدوية فيروس عوز المناعة البشرية نفسها. سوف يختبر طبيبك هذه التغييرات.</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا تفاقمت أيًا من الأعراض الجانبية، أو لاحظت أي أعراض جانبية غير مدرجة في هذه النشرة فأخبر طبيبك أو مقدم الرعاية الصحية أو الصيدلي. يمكنك أيضاً الإبلاغ عن الأعراض الجانبية مباشرة عن طريق نظام الإبلاغ الوطني:</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن الإخبار عن الأعراض الجانبية أن يساعد في توفير مزيد من المعلومات حول سلامة هذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن نظر ومتناول الأطفال.</p><p dir="RTL">لا تستعمل هذا الدواء بعد تاريخ انتهاء الصلاحية المذكورة على الكرتون والقنينة بعد أحرف &quot;EXP&quot;. تاريخ انتهاء الصلاحية يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">يخزن في العلبة الأصلية من أجل حمايته من الرطوبة. احفظ القنينة مغلقة بإحكام.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستعمل. من شأن هذه التدابير أن تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المواد الفعالة هي</strong> إميتريسيتاباين وتينوفوفير ألافينامايد. كل قرص مغلف بغشاء من ديسكوفي يحتوي على 200&nbsp;ملغم من إميتريسيتاباين وفومارات تينوفوفير ألافينامايد التي تعادل 10&nbsp;ملغم من تينوفوفير ألافينامايد.</p><p dir="RTL"><strong>المكونات الأخرى هي</strong></p><p dir="RTL"><em>لب القرص</em>:</p><p dir="RTL">السليلوز المكروي البلوري، كروسكارميللوز الصوديوم، ستيرات المغنيسيوم.</p><p dir="RTL"><em>غشاء التغليف</em>:</p><p dir="RTL">كحول البولي فينيل، ثاني أكسيد التيتانيوم، ماكروغول 3350، التلك، وأوكسيد الحديد الأسود (E172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل ديسكوفي وما هي محتويات العلبة</strong></p><p dir="RTL">أقراص ديسكوفي المغلفة بغشاء هي أقراص رمادية، مستطيلة الشكل مطبوع عليها من جانب واحد الأحرف &quot;GSI&quot; والعدد &quot;210&quot; على الجانب الآخر من القرص.</p><p dir="RTL">يأتي دواء ديسكوفي في قنينة من 30 قرصًا (والتي تحتوي على هلام السيليكا المجفف والذي يجب أن يبقى في القنينة للمساعدة في حماية الأقراص). ويوجد هلام السيليكا المجفف في كيس منفصل أو أسطوانة ويجب عدم بلعه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر حجم العلبة التالية: كرتون خارجي يحتوي على قنينة واحدة تحتوي على 30 قرصاً مغلفاً بغشاء.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق والمصنع المسؤول عن التغليف وإصدار التشغيلة:</strong></p><p dir="RTL">جيلياد للعلوم أيرلندا يو سي</p><p dir="RTL">حديقة &nbsp;آي دي إيه للأعمال و التكنولوجيا</p><p dir="RTL">كاريغتوهيل</p><p dir="RTL">مقاطعة كورك</p><p dir="RTL">أيرلندا</p><p dir="RTL">هاتف: +353 (0) 21 483 5500</p><p dir="RTL">فاكس:&nbsp;+353 (0) 21 483 5518</p><p dir="RTL">البريد الإلكتروني:&nbsp;csafety@gilead.com</p><p dir="RTL"><strong>المصنع المسؤول عن التصنيع والتغليف</strong></p><p dir="RTL">باثيون إنك.</p><p dir="RTL">تورونتو للعمليات الإقليمية</p><p dir="RTL">2100 سينتكس كورت</p><p dir="RTL">ميسيسوجا</p><p dir="RTL">L5N 7K9 أونتاريو</p><p dir="RTL">كندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Descovy 200 mg/10 mg film coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet.

Grey, rectangular shaped, film coated tablet of dimensions 12.5 mm x 6.4 mm debossed with “GSI” on one side and “210” on the other side of the tablet.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12&nbsp;years and older with body weight at least 35&nbsp;kg) infected with human immunodeficiency virus type&nbsp;1 (HIV‑1) (see sections&nbsp;4.2 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy should be initiated by a physician experienced in the management of HIV&nbsp;infection.</p><p><u>Posology</u></p><p>Descovy should be administered as shown in Table&nbsp;1.</p><p><strong>Table&nbsp;1: Dose of Descovy according to third agent in the HIV treatment regimen</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:433px"><tbody><tr><td style="vertical-align:top"><p>Dose of Descovy</p></td><td style="vertical-align:top"><p>Third agent in HIV treatment regimen (see section&nbsp;4.5)</p></td></tr><tr><td style="vertical-align:top"><p>Descovy 200/10&nbsp;mg once daily</p></td><td style="vertical-align:top"><p>Atazanavir with ritonavir or cobicistat</p><p>Darunavir with ritonavir or cobicistat<sup>1</sup></p><p>Lopinavir with ritonavir</p></td></tr><tr><td style="vertical-align:top"><p>Descovy 200/25&nbsp;mg once daily</p></td><td style="vertical-align:top"><p>Dolutegravir, efavirenz, maraviroc, nevirapine, rilpivirine, raltegravir</p></td></tr></tbody></table><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp; Descovy 200/10&nbsp;mg in combination with darunavir 800&nbsp;mg and cobicistat 150&nbsp;mg, administered as a fixed-dose combination tablet, was studied in treatment-naive subjects, see section&nbsp;5.1.</p><p>&nbsp;</p><p><em>Missed doses</em></p><p>If the patient misses a dose of Descovy within 18&nbsp;hours of the time it is usually taken, the patient should take Descovy as soon as possible and resume the normal dosing schedule. &nbsp;If a patient misses a dose of Descovy by more than 18&nbsp;hours, the patient should not take the missed dose and simply resume the usual dosing schedule.</p><p>If the patient vomits within 1&nbsp;hour of taking Descovy another tablet should be taken.</p><p><em>Elderly</em></p><p>No dose adjustment of Descovy is required in elderly patients (see sections&nbsp;5.1 and 5.2).</p><p><em>Renal impairment</em></p><p>No dose adjustment of Descovy is required in adults or adolescents (aged at least 12&nbsp;years and of at least 35&nbsp;kg body weight) with estimated creatinine clearance (CrCl) &ge;&nbsp;30&nbsp;mL/min. Descovy should be discontinued in patients with estimated CrCl that declines below 30&nbsp;mL/min during treatment (see section&nbsp;5.2).</p><p>No dose adjustment of Descovy is required in adults with end&nbsp;stage renal disease (estimated CrCl&nbsp;&lt;&nbsp;15&nbsp;mL/min) on chronic haemodialysis; however, Descovy should generally be avoided but may be used in these patients if the potential benefits are considered to outweigh the potential risks (see sections&nbsp;4.4 and 5.2). &nbsp;On days of haemodialysis, Descovy should be administered after completion of haemodialysis treatment.</p><p>Descovy should be avoided in patients with estimated CrCl&nbsp;&ge;&nbsp;15&nbsp;mL/min and &lt;&nbsp;30&nbsp;mL/min, or &lt;&nbsp;15&nbsp;mL/min who are not on chronic haemodialysis, as the safety of Descovy has not been established in these populations.</p><p>No data are available to make dose recommendations in children less than&nbsp;18&nbsp;years with end&nbsp;stage renal disease.</p><p><em>Hepatic impairment</em></p><p>No dose adjustment of Descovy is required in patients with hepatic impairment. &nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Descovy in children younger than 12&nbsp;years of age, or weighing &lt;&nbsp;35&nbsp;kg, have not yet been established.&nbsp; No data are available.</p><p><u>Method of administration</u></p><p>Oral use.</p><p>Descovy should be taken once daily with or without food (see section&nbsp;5.2). &nbsp;It is recommended that the film‑coated tablet is not chewed or crushed due to the bitter taste.</p><p>For patients who are unable to swallow the tablet whole, the tablet may be split in half and both halves taken once after the other, ensuring that the full dose is taken immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>While effective viral suppression with antiretroviral therapy has been proven to substantially reduce the risk of sexual transmission, a residual risk cannot be excluded. &nbsp;Precautions to prevent transmission should be taken in accordance with national guidelines.</p><p>&nbsp;</p><p><u>Patients co‑infected with HIV and hepatitis&nbsp;B or&nbsp;C virus</u></p><p>Patients with chronic hepatitis&nbsp;B or&nbsp;C treated with antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.</p><p>The safety and efficacy of Descovy in patients co‑infected with HIV‑1 and hepatitis&nbsp;C virus (HCV) have not been established.</p><p>Tenofovir alafenamide is active against hepatitis&nbsp;B virus (HBV).&nbsp; Discontinuation of Descovy therapy in patients co‑infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis. &nbsp;Patients co‑infected with HIV and HBV who discontinue Descovy should be closely monitored with both clinical and laboratory follow‑up for at least several months after stopping treatment.</p><p><u>Liver disease</u></p><p>The safety and efficacy of Descovy in patients with significant underlying liver disorders have not been established (see sections&nbsp;4.2 and 5.2).</p><p>Patients with pre‑existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice. &nbsp;If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.</p><p><u>Weight and metabolic parameters</u></p><p>An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy. &nbsp;Such changes may in part be linked to disease control and life style. &nbsp;For lipids, there is in some cases evidence for a treatment effect, while for weight gain there is no strong evidence relating this to any particular treatment.&nbsp; For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines. &nbsp;Lipid disorders should be managed as clinically appropriate.</p><p><u>Mitochondrial dysfunction following exposure <em>in&nbsp;utero</em></u></p><p>Nucleos(t)ide analogues may impact mitochondrial function to a variable degree, which is most pronounced with stavudine, didanosine and zidovudine.&nbsp; There have been reports of mitochondrial dysfunction in HIV negative infants exposed <em>in&nbsp;utero</em> and/or postnatally to nucleoside analogues; these have predominantly concerned treatment with regimens containing zidovudine.&nbsp; The main adverse reactions reported are haematological disorders (anaemia, neutropenia) and metabolic disorders (hyperlactatemia, hyperlipasemia).&nbsp; These events have often been transitory.&nbsp; Late onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour).&nbsp; Whether such neurological disorders are transient or permanent is currently unknown.&nbsp; These findings should be considered for any child exposed <em>in&nbsp;utero</em> to nucleos(t)ide analogues, who present with severe clinical findings of unknown aetiology, particularly neurologic findings.&nbsp; These findings do not affect current national recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV.</p><p><u>Immune Reactivation Syndrome</u></p><p>In HIV&nbsp;infected patients with severe immune deficiency at the time of institution of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.&nbsp; Typically, such reactions have been observed within the first few weeks or months of initiation of CART.&nbsp; Relevant examples include cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and <em>Pneumocystis </em><em>jirovecii</em> pneumonia.&nbsp; Any inflammatory symptoms should be evaluated and treatment instituted when necessary.</p><p>Autoimmune disorders (such as Graves&rsquo; disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable, and these events can occur many months after initiation of treatment.</p><p><u>Patients with HIV‑1 harbouring mutations</u></p><p>Descovy should be avoided in antiretroviral-experienced patients with HIV‑1 harbouring the K65R mutation (see section&nbsp;5.1).</p><p><u>Triple nucleoside therapy</u></p><p>There have been reports of a high rate of virological failure and of emergence of resistance at an early stage when tenofovir disoproxil was combined with lamivudine and abacavir as well as with lamivudine and didanosine as a once daily regimen.&nbsp; Therefore, the same problems may be seen if Descovy is administered with a third nucleoside analogue.</p><p><u>Opportunistic infections</u></p><p>Patients receiving Descovy or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV&nbsp;infection, and, therefore, should remain under close clinical observation by physicians experienced in the treatment of patients with HIV&nbsp;associated diseases.</p><p><u>Osteonecrosis</u></p><p>Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV&nbsp;disease and/or long‑term exposure to CART. &nbsp;Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.</p><p><u>Nephrotoxicity</u></p><p>A potential risk of nephrotoxicity resulting from chronic exposure to low levels of tenofovir due to dosing with tenofovir alafenamide cannot be excluded (see section&nbsp;5.3).</p><p>It is recommended that renal function is assessed in all patients prior to, or when initiating, therapy with Descovy and that it is also monitored during therapy in all patients as clinically appropriate.&nbsp; In patients who develop clinically significant decreases in renal function, or evidence of proximal renal tubulopathy, discontinuation of Descovy should be considered.</p><p><u>Patients with </u><u>end&nbsp;stage renal disease on chronic haemodialysis</u></p><p>Descovy should generally be avoided, but may be used in adults with end stage renal disease (estimated CrCl&nbsp;&lt;&nbsp;15&nbsp;mL/min) on chronic haemodialysis if the potential benefits outweigh the potential risks (see section&nbsp;4.2). &nbsp;In a study of emtricitabine + tenofovir alafenamide in combination with elvitegravir + cobicistat as a fixed-dose combination tablet (E/C/F/TAF) in HIV-1 infected adults with end stage renal disease (estimated CrCl&nbsp;&lt;&nbsp;15 mL/min) on chronic haemodialysis, efficacy was maintained through 48&nbsp;weeks but emtricitabine exposure was significantly higher than in patients with normal renal function.&nbsp; Although there were no new safety issues identified, the implications of increased emtricitabine exposure remain uncertain (see sections&nbsp;4.8 and 5.2).</p><p><u>Co‑administration of other medicinal products</u></p><p>The co‑administration of Descovy is not recommended with certain anticonvulsants (e.g., carbamazepine, oxcarbazepine, phenobarbital and phenytoin), antimycobacterials (e.g., rifampicin, rifabutin, rifapentine), St.&nbsp;John&rsquo;s wort and HIV&nbsp;protease inhibitors (PIs) other than atazanavir, lopinavir and darunavir (see section&nbsp;4.5).</p><p>Descovy should not be administered concomitantly with medicinal products containing tenofovir alafenamide, tenofovir disoproxil, emtricitabine, lamivudine or adefovir dipivoxil.</p><p><u>Excipients</u></p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p><p>Descovy should not be administered concomitantly with medicinal products containing tenofovir alafenamide, tenofovir disoproxil, emtricitabine, lamivudine or adefovir dipivoxil.</p><p><u>Emtricitabine</u></p><p><em>In&nbsp;vitro</em> and clinical pharmacokinetic drug-drug interaction studies have shown that the potential for CYP‑mediated interactions involving emtricitabine with other medicinal products is low. &nbsp;Co‑administration of emtricitabine with medicinal products that are eliminated by active tubular secretion may increase concentrations of emtricitabine, and/or the co‑administered medicinal product. &nbsp;Medicinal products that decrease renal function may increase concentrations of emtricitabine.</p><p><u>Tenofovir alafenamide</u></p><p>Tenofovir alafenamide is transported by P‑glycoprotein (P‑gp) and breast cancer resistance protein (BCRP). &nbsp;Medicinal products that strongly affect P‑gp and BCRP activity may lead to changes in tenofovir alafenamide absorption. &nbsp;Medicinal products that induce P‑gp activity (e.g., rifampicin, rifabutin, carbamazepine, phenobarbital) are expected to decrease the absorption of tenofovir alafenamide, resulting in decreased plasma concentration of tenofovir alafenamide, which may lead to loss of therapeutic effect of Descovy and development of resistance. &nbsp;Co‑administration of Descovy with other medicinal products that inhibit P‑gp and BCRP activity (e.g., cobicistat, ritonavir, ciclosporin) is expected to increase the absorption and plasma concentration of tenofovir alafenamide. &nbsp;Based on data from an <em>in&nbsp;vitro</em> study, co‑administration of tenofovir alafenamide and xanthine oxidase inhibitors (e.g., febuxostat) is not expected to increase systemic exposure to tenofovir <em>in&nbsp;vivo</em>.</p><p>Tenofovir alafenamide is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 <em>in&nbsp;vitro</em>.&nbsp; It is not an inhibitor or inducer of CYP3A <em>in&nbsp;vivo</em>. &nbsp;Tenofovir alafenamide is a substrate of OATP1B1 and OATP1B3 <em>in&nbsp;vitro</em>. &nbsp;The distribution of tenofovir alafenamide in the body may be affected by the activity of OATP1B1 and OATP1B3.</p><p><u>Other interactions</u></p><p>Tenofovir alafenamide is not an inhibitor of human uridine diphosphate glucuronosyltransferase (UGT)&nbsp;1A1 <em>in&nbsp;vitro</em>.&nbsp; It is not known whether tenofovir alafenamide is an inhibitor of other UGT&nbsp;enzymes. &nbsp;Emtricitabine did not inhibit the glucuronidation reaction of a non-specific UGT substrate <em>in&nbsp;vitro</em>.</p><p>Interactions between the components of Descovy and potential co‑administered medicinal products are listed in Table&nbsp;2 (increase is indicated as &ldquo;&uarr;&rdquo;, decrease as &ldquo;&darr;&rdquo;, no change as &ldquo;&harr;&rdquo;). &nbsp;The interactions described are based on studies conducted with Descovy, or the components of Descovy as individual agents and/or in combination, or are potential drug-drug interactions that may occur with Descovy.</p><p><strong>Table&nbsp;2: Interactions between the individual components of Descovy and other medicinal products</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><thead><tr><td style="vertical-align:top"><p>Medicinal product by therapeutic areas<sup>1</sup></p></td><td colspan="2" style="vertical-align:top"><p>Effects on medicinal product levels.</p><p>Mean percent change in AUC, C<sub>max</sub>, C<sub>min</sub><sup>2</sup></p></td><td style="vertical-align:top"><p>Recommendation concerning co‑administration with Descovy</p></td></tr></thead><tbody><tr><td colspan="4" style="vertical-align:top"><p><em>ANTI-INFECTIVES</em></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Antifungals</p></td></tr><tr><td style="vertical-align:top"><p>Ketoconazole</p><p>Itraconazole</p></td><td colspan="2" style="vertical-align:top"><p>Interaction not studied with either of the components of Descovy.</p><p>&nbsp;</p><p>Co‑administration of ketoconazole or itraconazole, which are potent P‑gp inhibitors, is expected to increase plasma concentrations of tenofovir alafenamide.</p></td><td style="vertical-align:top"><p>The recommended dose of Descovy is 200/10&nbsp;mg once daily.</p></td></tr><tr><td style="vertical-align:top"><p>Fluconazole</p><p>Isavuconazole</p></td><td colspan="2" style="vertical-align:top"><p>Interaction not studied with either of the components of Descovy.</p><p>&nbsp;</p><p>Co‑administration of fluconazole or isavuconazole may increase plasma concentrations of tenofovir alafenamide.</p></td><td style="vertical-align:top"><p>Dose Descovy according to the concomitant antiretroviral (see section&nbsp;4.2).</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Antimycobacterials</p></td></tr><tr><td style="vertical-align:top"><p>Rifabutin</p><p>Rifampicin</p><p>Rifapentine</p></td><td colspan="2" style="vertical-align:top"><p>Interaction not studied with either of the components of Descovy.</p><p>&nbsp;</p><p>Co‑administration of rifampicin, rifabutin, and rifapentine, all of which are P‑gp inducers, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance.</p></td><td style="vertical-align:top"><p>Co‑administration of Descovy and rifabutin rifampicin, or rifapentine is not recommended.</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Anti-hepatitis&nbsp;C virus medicinal products</p></td></tr><tr><td style="vertical-align:top"><p>Ledipasvir (90&nbsp;mg once daily)/ sofosbuvir (400&nbsp;mg once daily), emtricitabine (200&nbsp;mg once daily)/ tenofovir alafenamide (10&nbsp;mg once daily)<sup> 3</sup></p></td><td colspan="2" style="vertical-align:top"><p>Ledipasvir:</p><p>AUC: &uarr;&nbsp;79%</p><p>C<sub>max</sub>: &uarr;&nbsp;65%</p><p>C<sub>min</sub>: &uarr;&nbsp;93%</p><p>&nbsp;</p><p>Sofosbuvir:</p><p>AUC: &uarr;&nbsp;47%</p><p>C<sub>max</sub>: &uarr;&nbsp;29%</p><p>&nbsp;</p><p>Sofosbuvir metabolite GS‑331007:</p><p>AUC: &uarr;&nbsp;48%</p><p>C<sub>max</sub>: &harr;</p><p>C<sub>min</sub>: &uarr;&nbsp;66%</p><p>&nbsp;</p><p>Emtricitabine:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>C<sub>min</sub>: &harr;</p><p>&nbsp;</p><p>Tenofovir alafenamide:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p></td><td style="vertical-align:top"><p>No dose adjustment of ledipasvir or sofosbuvir is required. &nbsp;Dose Descovy according to the concomitant antiretroviral (see section&nbsp;4.2).</p></td></tr><tr><td style="vertical-align:top"><p>Ledipasvir (90&nbsp;mg once daily)/ sofosbuvir (400&nbsp;mg once daily), emtricitabine (200&nbsp;mg once daily)/ tenofovir alafenamide (25&nbsp;mg once daily)<sup> 4</sup></p></td><td colspan="2" style="vertical-align:top"><p>Ledipasvir:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>C<sub>min</sub>: &harr;</p><p>&nbsp;</p><p>Sofosbuvir:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>&nbsp;</p><p>Sofosbuvir metabolite GS‑331007:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>C<sub>min</sub>: &harr;</p><p>&nbsp;</p><p>Emtricitabine:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>C<sub>min</sub>: &harr;</p><p>&nbsp;</p><p>Tenofovir alafenamide:</p><p>AUC: &uarr;&nbsp;32%</p><p>C<sub>max</sub>: &harr;</p></td><td style="vertical-align:top"><p>No dose adjustment of ledipasvir or sofosbuvir is required. &nbsp;Dose Descovy according to the concomitant antiretroviral (see section&nbsp;4.2).</p></td></tr><tr><td style="vertical-align:top"><p>Sofosbuvir (400 mg once daily)/</p><p>velpatasvir (100 mg once daily), emtricitabine (200 mg once daily)/ tenofovir alafenamide</p><p>(10 mg once daily)<sup>3</sup></p></td><td colspan="2" style="vertical-align:top"><p>Sofosbuvir:</p><p>AUC: &uarr; 37%</p><p>C<sub>max</sub>: &harr;</p><p>&nbsp;</p><p>Sofosbuvir metabolite GS-331007:</p><p>AUC: &uarr; 48%</p><p>C<sub>max</sub>: &harr;</p><p>C<sub>min</sub>: &uarr; 58%</p><p>&nbsp;</p><p>Velpatasvir:</p><p>AUC: &uarr; 50%</p><p>C<sub>max</sub>: &uarr; 30%</p><p>C<sub>min</sub>: &uarr; 60%</p><p>&nbsp;</p><p>Emtricitabine:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>C<sub>min</sub>: &harr;</p><p>&nbsp;</p><p>Tenofovir alafenamide:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &darr; 20%</p></td><td rowspan="2" style="vertical-align:top"><p>No dose adjustment of sofosbuvir, velpatasvir or voxilaprevir is required.&nbsp; Dose Descovy according to the concomitant antiretroviral (see section 4.2).</p></td></tr><tr><td style="vertical-align:top"><p>Sofosbuvir/velpatasvir/</p><p>voxilaprevir (400&nbsp;mg/100&nbsp;mg/100&nbsp;mg+100&nbsp;mg once daily)<sup>7</sup>/</p><p>emtricitabine (200&nbsp;mg once daily)/ tenofovir alafenamide (10&nbsp;mg once daily)<sup>3</sup></p></td><td colspan="2" style="vertical-align:top"><p>Sofosbuvir:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &uarr;&nbsp;27%</p><p>&nbsp;</p><p>Sofosbuvir metabolite GS-331007:</p><p>AUC: &uarr;&nbsp;43%</p><p>C<sub>max</sub>: &harr;</p><p>&nbsp;</p><p>Velpatasvir:</p><p>AUC: &harr;</p><p>C<sub>min</sub>: &uarr;&nbsp;46%</p><p>C<sub>max</sub>: &harr;</p><p>&nbsp;</p><p>Voxilaprevir:</p><p>AUC: &uarr;&nbsp;171%</p><p>C<sub>min</sub>: &uarr;&nbsp;350%</p><p>C<sub>max</sub>: &uarr;&nbsp;92%</p><p>&nbsp;</p><p>Emtricitabine:</p><p>AUC: &harr;</p><p>C<sub>min</sub>: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>&nbsp;</p><p>Tenofovir alafenamide:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &darr;&nbsp;21%</p></td></tr><tr><td style="vertical-align:top"><p>Sofosbuvir/velpatasvir/</p><p>voxilaprevir (400&nbsp;mg/100&nbsp;mg/100&nbsp;mg+100&nbsp;mg once daily)<sup>7</sup>/</p><p>emtricitabine (200&nbsp;mg once daily)/ tenofovir alafenamide (25&nbsp;mg once daily)<sup>4</sup></p></td><td colspan="2" style="vertical-align:top"><p>Sofosbuvir:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>&nbsp;</p><p>Sofosbuvir metabolite GS-331007:</p><p>AUC: &harr;</p><p>C<sub>min</sub>: &harr;</p><p>&nbsp;</p><p>Velpatasvir:</p><p>AUC: &harr;</p><p>C<sub>min</sub>: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>&nbsp;</p><p>Voxilaprevir:</p><p>AUC: &harr;</p><p>C<sub>min</sub>: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>&nbsp;</p><p>Emtricitabine:</p><p>AUC: &harr;</p><p>C<sub>min</sub>: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>&nbsp;</p><p>Tenofovir alafenamide:</p><p>AUC: &uarr;&nbsp;52%</p><p>C<sub>max</sub>: &uarr;&nbsp;32%</p></td><td style="vertical-align:top"><p>No dose adjustment of sofosbuvir, velpatasvir or voxilaprevir is required.&nbsp; Dose Descovy according to the concomitant antiretroviral (see section&nbsp;4.2).</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>ANTIRETROVIRALS</em></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>HIV&nbsp;protease inhibitors</p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir/cobicistat (300&nbsp;mg/150&nbsp;mg once daily), tenofovir alafenamide (10 mg)</p></td><td colspan="2" style="vertical-align:top"><p>Tenofovir alafenamide:</p><p>AUC: &uarr;&nbsp;75%</p><p>C<sub>max</sub>: &uarr;&nbsp;80%</p><p>&nbsp;</p><p>Atazanavir:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>C<sub>min</sub>: &harr;</p></td><td style="vertical-align:top"><p>The recommended dose of Descovy is 200/10&nbsp;mg once daily.</p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir/ritonavir (300/100&nbsp;mg once daily), tenofovir alafenamide (10&nbsp;mg)</p></td><td colspan="2" style="vertical-align:top"><p>Tenofovir alafenamide:</p><p>AUC: &uarr;&nbsp;91%</p><p>C<sub>max</sub>: &uarr;&nbsp;77%</p><p>&nbsp;</p><p>Atazanavir:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>C<sub>min</sub>: &harr;</p></td><td style="vertical-align:top"><p>The recommended dose of Descovy is 200/10&nbsp;mg once daily.</p></td></tr><tr><td style="vertical-align:top"><p>Darunavir/cobicistat (800/150&nbsp;mg once daily), tenofovir alafenamide (25&nbsp;mg once daily)<sup>5</sup></p></td><td colspan="2" style="vertical-align:top"><p>Tenofovir alafenamide:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>&nbsp;</p><p>Tenofovir:</p><p>AUC: &uarr;&nbsp;224%</p><p>C<sub>max</sub>: &uarr;&nbsp;216%</p><p>C<sub>min</sub>: &uarr;&nbsp;221%</p><p>&nbsp;</p><p>Darunavir:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>C<sub>min</sub>: &harr;</p></td><td style="vertical-align:top"><p>The recommended dose of Descovy is 200/10&nbsp;mg once daily.</p></td></tr><tr><td style="vertical-align:top"><p>Darunavir/ritonavir (800/100&nbsp;mg once daily), tenofovir alafenamide (10&nbsp;mg once daily)</p></td><td colspan="2" style="vertical-align:top"><p>Tenofovir alafenamide:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>&nbsp;</p><p>Tenofovir:</p><p>AUC: &uarr;&nbsp;105%</p><p>C<sub>max</sub>: &uarr;&nbsp;142%</p><p>&nbsp;</p><p>Darunavir:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>C<sub>min</sub>: &harr;</p></td><td style="vertical-align:top"><p>The recommended dose of Descovy is 200/10&nbsp;mg once daily.</p></td></tr><tr><td style="vertical-align:top"><p>Lopinavir/ritonavir (800/200&nbsp;mg once daily), tenofovir alafenamide (10&nbsp;mg once daily)</p></td><td colspan="2" style="vertical-align:top"><p>Tenofovir alafenamide:</p><p>AUC: &uarr;&nbsp;47%</p><p>C<sub>max</sub>: &uarr;&nbsp;119%</p><p>&nbsp;</p><p>Lopinavir:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>C<sub>min</sub>: &harr;</p></td><td style="vertical-align:top"><p>The recommended dose of Descovy is 200/10&nbsp;mg once daily.</p></td></tr><tr><td style="vertical-align:top"><p>Tipranavir/ritonavir</p></td><td colspan="2" style="vertical-align:top"><p>Interaction not studied with either of the components of Descovy.</p><p>&nbsp;</p><p>Tipranavir/ritonavir results in P‑gp induction.&nbsp; Tenofovir alafenamide exposure is expected to decrease when tipranavir/ritonavir is used in combination with Descovy.</p></td><td style="vertical-align:top"><p>Co‑administration with Descovy is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Other protease inhibitors</p></td><td colspan="2" style="vertical-align:top"><p>Effect is unknown.</p></td><td style="vertical-align:top"><p>There are no data available to make dosing recommendations for co‑administration with other protease inhibitors.</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Other HIV antiretrovirals</p></td></tr><tr><td style="vertical-align:top"><p>Dolutegravir (50&nbsp;mg once daily), tenofovir alafenamide (10&nbsp;mg once daily)<sup>3</sup></p></td><td colspan="2" style="vertical-align:top"><p>Tenofovir alafenamide:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>&nbsp;</p><p>Dolutegravir:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>C<sub>min</sub>: &harr;</p></td><td style="vertical-align:top"><p>The recommended dose of Descovy is 200/25&nbsp;mg once daily.</p></td></tr><tr><td style="vertical-align:top"><p>Rilpivirine (25&nbsp;mg once daily), tenofovir alafenamide (25&nbsp;mg once daily)</p></td><td colspan="2" style="vertical-align:top"><p>Tenofovir alafenamide:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>&nbsp;</p><p>Rilpivirine:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>C<sub>min</sub>: &harr;</p></td><td style="vertical-align:top"><p>The recommended dose of Descovy is 200/25&nbsp;mg once daily.</p></td></tr><tr><td style="vertical-align:top"><p>Efavirenz (600&nbsp;mg once daily), tenofovir alafenamide (40&nbsp;mg once daily)<sup>4</sup></p></td><td colspan="2" style="vertical-align:top"><p>Tenofovir alafenamide:</p><p>AUC: &darr;&nbsp;14%</p><p>C<sub>max</sub>: &darr;&nbsp;22%</p></td><td style="vertical-align:top"><p>The recommended dose of Descovy is 200/25&nbsp;mg once daily.</p></td></tr><tr><td style="vertical-align:top"><p>Maraviroc</p><p>Nevirapine</p><p>Raltegravir</p></td><td colspan="2" style="vertical-align:top"><p>Interaction not studied with either of the components of Descovy.</p><p>&nbsp;</p><p>Tenofovir alafenamide exposure is not expected to be affected by maraviroc, nevirapine</p><p>or raltegravir, nor is it expected to affect the metabolic and excretion pathways relevant to maraviroc, nevirapine or raltegravir.</p></td><td style="vertical-align:top"><p>The recommended dose of Descovy is 200/25&nbsp;mg once daily.</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>ANTICONVULSANTS</em></p></td></tr><tr><td style="vertical-align:top"><p>Oxcarbazepine</p><p>Phenobarbital</p><p>Phenytoin</p></td><td colspan="2" style="vertical-align:top"><p>Interaction not studied with either of the components of Descovy.</p><p>&nbsp;</p><p>Co‑administration of oxcarbazepine, phenobarbital, or phenytoin, all of which are P‑gp inducers, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance.</p></td><td style="vertical-align:top"><p>Co‑administration of Descovy and oxcarbazepine, phenobarbital or phenytoin is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Carbamazepine (titrated from 100&nbsp;mg to 300&nbsp;mg twice a day), emtricitabine/tenofovir alafenamide (200&nbsp;mg/25&nbsp;mg once daily)<sup> 5,6</sup></p></td><td colspan="2" style="vertical-align:top"><p>Tenofovir alafenamide:</p><p>AUC: &darr;&nbsp;55%</p><p>C<sub>max</sub>: &darr;&nbsp;57%</p><p>&nbsp;</p><p>Co‑administration of carbamazepine, a P‑gp inducer, decreases tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance.</p></td><td style="vertical-align:top"><p>Co‑administration of Descovy and carbamazepine is not recommended.</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>ANTIDEPRESSANTS</em></p></td></tr><tr><td style="vertical-align:top"><p>Sertraline (50&nbsp;mg once daily), tenofovir alafenamide (10&nbsp;mg once daily)<sup>3</sup></p></td><td colspan="2" style="vertical-align:top"><p>Tenofovir alafenamide:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>&nbsp;</p><p>Sertraline:</p><p>AUC: &uarr;&nbsp;9%</p><p>C<sub>max</sub>: &uarr;&nbsp;14%</p></td><td style="vertical-align:top"><p>No dose adjustment of sertraline is required. &nbsp;Dose Descovy according to the concomitant antiretroviral (see section&nbsp;4.2).</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>HERBAL PRODUCTS</em></p></td></tr><tr><td style="vertical-align:top"><p>St.&nbsp;John&rsquo;s wort (<em>Hypericum perforatum</em>)</p></td><td style="vertical-align:top"><p>Interaction not studied with either of the components of Descovy.</p><p>&nbsp;</p><p>Co‑administration of St.&nbsp;John&rsquo;s wort, a P‑gp inducer, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance.</p></td><td colspan="2" style="vertical-align:top"><p>Co‑administration of Descovy with St.&nbsp;John&rsquo;s wort is not recommended.</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>IMMUNOSUPPRESSANTS</em></p></td></tr><tr><td style="vertical-align:top"><p>Ciclosporin</p></td><td style="vertical-align:top"><p>Interaction not studied with either of the components of Descovy.</p><p>&nbsp;</p><p>Co-administration of ciclosporin, a potent P‑gp inhibitor, is expected to increase plasma concentrations of tenofovir alafenamide.</p></td><td colspan="2" style="vertical-align:top"><p>The recommended dose of Descovy is 200/10&nbsp;mg once daily.</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>ORAL CONTRACEPTIVES</em></p></td></tr><tr><td style="vertical-align:top"><p>Norgestimate (0.180/0.215/0.250&nbsp;mg once daily), ethinylestradiol (0.025&nbsp;mg once daily), emtricitabine/tenofovir alafenamide (200/25&nbsp;mg once daily)<sup>5</sup></p></td><td style="vertical-align:top"><p>Norelgestromin:</p><p>AUC: &harr;</p><p>C<sub>min</sub>: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>&nbsp;</p><p>Norgestrel:</p><p>AUC: &harr;</p><p>C<sub>min</sub>: &harr;</p><p>C<sub>max</sub>: &harr;</p><p>&nbsp;</p><p>Ethinylestradiol:</p><p>AUC: &harr;</p><p>C<sub>min</sub>: &harr;</p><p>C<sub>max:</sub> &harr;</p></td><td colspan="2" style="vertical-align:top"><p>No dose adjustment of norgestimate/ethinylestradiol is required.&nbsp; Dose Descovy according to the concomitant antiretroviral (see section&nbsp;4.2).</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>SEDATIVES/HYPNOTICS</em></p></td></tr><tr><td style="vertical-align:top"><p>Orally administered midazolam (2.5&nbsp;mg single dose), tenofovir alafenamide (25&nbsp;mg once daily)</p></td><td style="vertical-align:top"><p>Midazolam:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>No dose adjustment of midazolam is required. &nbsp;Dose Descovy according to the concomitant antiretroviral (see section&nbsp;4.2).</p></td></tr><tr><td style="vertical-align:top"><p>Intravenously administered midazolam (1&nbsp;mg single dose), tenofovir alafenamide (25&nbsp;mg once daily)</p></td><td style="vertical-align:top"><p>Midazolam:</p><p>AUC: &harr;</p><p>C<sub>max</sub>: &harr;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp; When doses are provided, they are the doses used in clinical drug-drug interaction studies.</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp; When data are available from drug-drug interaction studies.</p><p><sup>3</sup>&nbsp;&nbsp;&nbsp;&nbsp; Study conducted with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fixed-dose combination tablet.</p><p><sup>4</sup>&nbsp;&nbsp;&nbsp;&nbsp; Study conducted with emtricitabine/rilpivirine/tenofovir alafenamide fixed-dose combination tablet.</p><p><sup>5</sup>&nbsp;&nbsp;&nbsp;&nbsp; Study conducted with Descovy.</p><p><sup>6</sup>&nbsp;&nbsp;&nbsp;&nbsp; Emtricitabine/tenofovir alafenamide was taken with food in this study.</p><p><sup>7</sup>&nbsp;&nbsp;&nbsp;&nbsp; Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposurers expected in HCV-infected patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate and well-controlled studies of Descovy or its components in pregnant women. &nbsp;There are no or limited data (less than 300&nbsp;pregnancy outcomes) from the use of tenofovir alafenamide in pregnant women. &nbsp;However, a large amount of data on pregnant women (more than 1,000&nbsp;exposed outcomes) indicate no malformative nor foetal/neonatal toxicity associated with emtricitabine.</p><p>Animal studies do not indicate direct or indirect harmful effects of emtricitabine with respect to fertility parameters, pregnancy, foetal development, parturition or postnatal development. &nbsp;Studies of tenofovir alafenamide in animals have shown no evidence of harmful effects on fertility parameters, pregnancy, or foetal development (see section&nbsp;5.3).</p><p>Descovy should be used during pregnancy only if the potential benefit justifies the potential risk to the&nbsp;foetus.</p><p><u>Breast-feeding</u></p><p>It is not known whether tenofovir alafenamide is excreted in human milk. &nbsp;Emtricitabine is excreted in human milk. &nbsp;In animal studies it has been shown that tenofovir is excreted in milk.</p><p>There is insufficient information on the effects of emtricitabine and tenofovir in newborns/infants. &nbsp;Therefore, Descovy should not be used during breast-feeding.</p><p>In order to avoid transmission of HIV to the infant it is recommended that HIV&nbsp;infected women do not breast-feed their infants under any circumstances.</p><p><u>Fertility</u></p><p>There are no data on fertility from the use of Descovy in humans. &nbsp;In animal studies there were no effects of emtricitabine and tenofovir alafenamide on mating or fertility parameters (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Descovy may have minor influence on the ability to drive and use machines. Patients should be informed that dizziness has been reported during treatment with Descovy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Assessment of adverse reactions is based on safety data from across all Phase&nbsp;2 and 3 studies in which HIV‑1&nbsp;infected patients received medicinal products containing emtricitabine and tenofovir alafenamide and from post-marketing experience.&nbsp; In clinical studies of treatment-na&iuml;ve adult patients receiving emtricitabine and tenofovir alafenamide with elvitegravir and cobicistat as the fixed-dose combination tablet elvitegravir 150&nbsp;mg/cobicistat 150&nbsp;mg/emtricitabine 200&nbsp;mg/tenofovir alafenamide (as fumarate) 10&nbsp;mg (E/C/F/TAF) through 144 weeks, the most frequently reported adverse reactions were diarrhoea (7%), nausea (11%), and headache (6%).</p><p>&nbsp;</p><p><u>Tabulated summary of adverse reactions</u></p><p>The adverse reactions in Table&nbsp;3 are listed by system organ class and frequency. &nbsp;Frequencies are defined as follows: very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10) and uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100).</p><p><strong>Table&nbsp;3: Tabulated list of adverse reactions<sup>1</sup></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p>Frequency</p></td><td><p>Adverse reaction</p></td></tr></thead><tbody><tr><td colspan="2"><p><em>Blood and lymphatic system disorders</em></p></td></tr><tr><td><p>Uncommon:</p></td><td><p>anaemia<sup>2</sup></p></td></tr><tr><td colspan="2"><p><em>Psychiatric disorders</em></p></td></tr><tr><td><p>Common:</p></td><td><p>abnormal dreams</p></td></tr><tr><td colspan="2"><p><em>Nervous system disorders</em></p></td></tr><tr><td><p>Common:</p></td><td><p>headache, dizziness</p></td></tr><tr><td colspan="2"><p><em>Gastrointestinal disorders</em></p></td></tr><tr><td><p>Very common:</p></td><td><p>nausea</p></td></tr><tr><td><p>Common:</p></td><td><p>diarrhoea, vomiting, abdominal pain, flatulence</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>dyspepsia</p></td></tr><tr><td colspan="2"><p><em>Skin and subcutaneous tissue disorders</em></p></td></tr><tr><td><p>Common:</p></td><td><p>rash</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>angioedema<sup>3, 4</sup>, pruritus, urticaria<sup>4</sup></p></td></tr><tr><td colspan="2"><p><em>Musculoskeletal and connective tissue disorders</em></p></td></tr><tr><td><p>Uncommon:</p></td><td><p>arthralgia</p></td></tr><tr><td colspan="2"><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td><p>Common:</p></td><td><p>fatigue</p></td></tr></tbody></table><p><sup>1</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>With the exception of angioedema, anaemia and urticaria (see footnotes&nbsp;2,3 and 4), all adverse reactions were identified from clinical studies of F/TAF containing products.&nbsp; The frequencies were derived from Phase&nbsp;3 E/C/F/TAF clinical studies in 866 treatment-na&iuml;ve adult patients through 144&nbsp;weeks of treatment (GS‑US‑292‑0104 and GS‑US‑292‑0111).</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp; This adverse reaction was not observed in the clinical studies of F/TAF-containing products but identified from clinical studies or post‑marketing experience for emtricitabine when used with other antiretrovirals.</p><p><sup>3</sup>&nbsp;&nbsp;&nbsp;&nbsp; This adverse reaction was identified through post-marketing surveillance for emtricitabine-containing products.</p><p><sup>4</sup>&nbsp;&nbsp; &nbsp;&nbsp;This adverse reaction was identified through post-marketing surveillance for tenofovir alafenamide-containing products.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em>Immune Reactivation Syndrome</em></p><p>In HIV&nbsp;infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. &nbsp;Autoimmune disorders (such as Graves&rsquo; disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable, and these events can occur many months after initiation of treatment (see section&nbsp;4.4).</p><p><em>Osteonecrosis</em></p><p>Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV&nbsp;disease or long‑term exposure to CART. &nbsp;The frequency of this is unknown (see section&nbsp;4.4).</p><p><em>Changes in lipid laboratory tests</em></p><p>In studies in treatment-na&iuml;ve patients, increases from baseline were observed in both the tenofovir alafenamide fumarate and tenofovir disoproxil fumarate containing treatment groups for the fasting lipid parameters total cholesterol, direct low‑density lipoprotein (LDL)‑ and high‑density lipoprotein (HDL)‑cholesterol, and triglycerides at Week&nbsp;144.&nbsp; The median increase from baseline for those parameters was greater in the E/C/F/TAF group compared with the elvitegravir 150&nbsp;mg/cobicistat 150&nbsp;mg/emtricitabine 200&nbsp;mg/tenofovir disoproxil (as fumarate) 245&nbsp;mg (E/C/F/TDF) group at Week&nbsp;144 (p&nbsp;&lt;&nbsp;0.001 for the difference between treatment groups for fasting total cholesterol, direct LDL‑ and HDL‑cholesterol, and triglycerides).&nbsp; The median (Q1, Q3) change from baseline in total cholesterol to HDL‑cholesterol ratio at Week&nbsp;144 was 0.2 (‑0.3, 0.7) in the E/C/F/TAF group and 0.1 (‑0.4, 0.6) in the E/C/F/TDF group (p = 0.006 for the difference between treatment groups).</p><p>In a study of virologically suppressed patients switching from emtricitabine/tenofovir disoproxil fumarate to Descovy while maintaining the third antiretroviral agent (Study GS‑US‑311‑1089), increases from baseline were observed in the fasting lipid parameters total cholesterol, direct LDL cholesterol and triglycerides in the Descovy arm compared with little change in the emtricitabine/tenofovir disoproxil fumarate arm (p&nbsp;&le;&nbsp;0.009 for the difference between groups in changes from baseline).&nbsp; There was little change from baseline in median fasting values for HDL cholesterol and glucose, or in the fasting total cholesterol to HDL cholesterol ratio in either treatment arm at Week&nbsp;96.&nbsp; None of the changes was considered clinically relevant.</p><p>In a study of virologically suppressed adult patients switching from abacavir/lamivudine to Descovy while maintaining the third antiretroviral agent (Study GS‑US‑311‑1717), there were minimal changes in lipid parameters.</p><p><em>Metabolic parameters</em></p><p>Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see section&nbsp;4.4).</p><p><u>Paediatric population</u></p><p>The safety of emtricitabine and tenofovir alafenamide was evaluated through 48&nbsp;weeks in an open-label clinical study (GS‑US‑292‑0106) in which HIV‑1&nbsp;infected, treatment-na&iuml;ve paediatric patients aged 12 to &lt;&nbsp;18&nbsp;years received emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet. &nbsp;The safety profile of emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat in 50&nbsp;adolescent patients was similar to that in adults (see section&nbsp;5.1).</p><p><u>Other special populations</u></p><p><em>Patients with renal impairment</em></p><p>The safety of emtricitabine and tenofovir alafenamide was evaluated through 144&nbsp;weeks in an open-label clinical study (GS‑US‑292‑0112) in which 248&nbsp;HIV‑1&nbsp;infected patients who were either treatment-na&iuml;ve (n&nbsp;=&nbsp;6) or virologically suppressed (n&nbsp;=&nbsp;242) with mild to moderate renal impairment (estimated glomerular filtration rate by Cockcroft‑Gault method [eGFR<sub>CG</sub>]: 30‑69&nbsp;mL/min) received emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet. &nbsp;The safety profile in patients with mild to moderate renal impairment was similar to that in patients with normal renal function (see section&nbsp;5.1).</p><p>The safety of emtricitabine and tenofovir alafenamide was evaluated through 48&nbsp;weeks in a single arm, open‑label clinical study (GS‑US‑292‑1825) in which 55&nbsp;virologically suppressed HIV‑1 infected patients with end&nbsp;stage renal disease (eGFR<sub>CG</sub>&nbsp;&lt;&nbsp;15&nbsp;mL/min) on chronic haemodialysis received emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed‑dose combination tablet. &nbsp;There were no new safety issues identified in patients with end&nbsp;stage renal disease on chronic haemodialysis receiving emtricitabine and tenofovir alafenamide, in combination with elvitegravir and cobicistat as a fixed‑dose combination tablet (see section&nbsp;5.2).</p><p><em>Patients co‑infected with HIV and HBV</em></p><p>The safety of emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [E/C/F/TAF]) was evaluated in 72&nbsp;HIV/HBV co‑infected patients receiving treatment for HIV in an open-label clinical study (GS‑US‑292‑1249), through Week&nbsp;48, in which patients were switched from another antiretroviral regimen (which included tenofovir disoproxil fumarate [TDF] in 69 of 72 patients) to E/C/F/TAF. &nbsp;Based on these limited data, the safety profile of emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed‑dose combination tablet, in patients with HIV/HBV co‑infection, was similar to that in patients with HIV‑1&nbsp;monoinfection (see section&nbsp;4.4).</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. &nbsp;It allows continued monitoring of the benefit/risk balance of the medicinal product. &nbsp;Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p><u>To report any side effect(s):</u></p><p><strong>Saudi Arabia:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If overdose occurs the patient must be monitored for evidence of toxicity (see section&nbsp;4.8). &nbsp;Treatment of overdose with Descovy consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient.</p><p>&nbsp;</p><p>Emtricitabine can be removed by haemodialysis, which removes approximately 30% of the emtricitabine dose over a 3&nbsp;hour dialysis period starting within 1.5&nbsp;hours of emtricitabine dosing. &nbsp;Tenofovir is efficiently removed by haemodialysis with an extraction coefficient of approximately 54%. &nbsp;It is not known whether emtricitabine or tenofovir can be removed by peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antiviral for systemic use; antivirals for treatment of HIV&nbsp;infections, combinations. &nbsp;ATC code: J05AR17.</p><p><u>Mechanism of action</u></p><p>Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and nucleoside analogue of 2&rsquo;‑deoxycytidine. &nbsp;Emtricitabine is phosphorylated by cellular enzymes to form emtricitabine triphosphate. &nbsp;Emtricitabine triphosphate inhibits HIV&nbsp;replication through incorporation into viral deoxyribonucleic acid (DNA) by the HIV&nbsp;reverse transcriptase (RT), which results in DNA chain-termination. &nbsp;Emtricitabine has activity against HIV‑1, HIV‑2, and HBV.</p><p>Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI) and phosphonamidate prodrug of tenofovir (2&rsquo;‑deoxyadenosine monophosphate analogue). &nbsp;Tenofovir alafenamide is permeable into cells and due to increased plasma stability and intracellular activation through hydrolysis by cathepsin&nbsp;A, tenofovir alafenamide is more efficient than tenofovir disoproxil fumarate in concentrating tenofovir in peripheral blood mononuclear cells (PBMCs) or HIV&nbsp;target cells including lymphocytes and macrophages. &nbsp;Intracellular tenofovir is subsequently phosphorylated to the pharmacologically active metabolite tenofovir diphosphate. &nbsp;Tenofovir diphosphate inhibits HIV&nbsp;replication through incorporation into viral DNA by the HIV&nbsp;RT, which results in DNA chain-termination.</p><p>Tenofovir has activity against HIV‑1, HIV‑2, and HBV.</p><p><u>Antiviral activity <em>in&nbsp;vitro</em></u></p><p>Emtricitabine and tenofovir alafenamide demonstrated synergistic antiviral activity in cell culture. No&nbsp;antagonism was observed with emtricitabine or tenofovir alafenamide when combined with other antiretroviral agents.</p><p>The antiviral activity of emtricitabine against laboratory and clinical isolates of HIV‑1 was assessed in lymphoblastoid cell lines, the MAGI&nbsp;CCR5 cell line, and PBMCs. &nbsp;The 50% effective concentration (EC<sub>50</sub>) values for emtricitabine were in the range of 0.0013 to 0.64&nbsp;&mu;M. &nbsp;Emtricitabine displayed antiviral activity in cell culture against HIV‑1&nbsp;clades&nbsp;A, B, C, D, E, F, and G (EC<sub>50</sub> values ranged from 0.007 to 0.075&nbsp;&mu;M) and showed strain specific activity against HIV‑2 (EC<sub>50</sub> values ranged from 0.007 to 1.5&nbsp;&mu;M).</p><p>The antiviral activity of tenofovir alafenamide against laboratory and clinical isolates of HIV‑1&nbsp;subtype&nbsp;B was assessed in lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells and CD4+‑T&nbsp;lymphocytes. &nbsp;The EC<sub>50</sub> values for tenofovir alafenamide were in the range of 2.0 to 14.7&nbsp;nM. &nbsp;Tenofovir alafenamide displayed antiviral activity in cell culture against all HIV‑1&nbsp;groups (M, N, and O), including subtypes&nbsp;A, B, C, D, E, F, and G (EC<sub>50</sub> values ranged from 0.10 to 12.0&nbsp;nM) and showed strain specific activity against HIV‑2 (EC<sub>50</sub> values ranged from 0.91 to 2.63&nbsp;nM).</p><p><u>Resistance</u></p><p><em>In&nbsp;vitro</em></p><p>Reduced susceptibility to emtricitabine is associated with M184V/I mutations in HIV‑1&nbsp;RT.</p><p>HIV‑1&nbsp;isolates with reduced susceptibility to tenofovir alafenamide express a K65R mutation in HIV‑1&nbsp;RT; in addition, a K70E mutation in HIV‑1&nbsp;RT has been transiently observed.</p><p><em>In treatment-na&iuml;ve patients</em></p><p>In a pooled analysis of antiretroviral-na&iuml;ve patients receiving emtricitabine and tenofovir alafenamide (10&nbsp;mg) given with elvitegravir and cobicistat as a fixed-dose combination tablet in Phase 3 studies GS‑US‑292‑0104 and GS‑US‑292‑0111, genotyping was performed on plasma HIV‑1&nbsp;isolates from all patients with HIV‑1&nbsp;RNA &ge;&nbsp;400&nbsp;copies/mL at confirmed virological failure, at Week&nbsp;144, or at the time of early study drug discontinuation. &nbsp;Through Week&nbsp;144, the development of one or more primary emtricitabine, tenofovir alafenamide, or elvitegravir resistance-associated mutations was observed in HIV‑1&nbsp;isolates from 12 of 22&nbsp;patients with evaluable genotypic data from paired baseline and E/C/F/TAF treatment-failure isolates (12 of 866&nbsp;patients [1.4%]) compared with 12 of 20&nbsp;treatment-failure isolates from patients with evaluable genotypic data in the E/C/F/TDF group (12 of 867&nbsp;patients [1.4%]). &nbsp;In the E/C/F/TAF group, the mutations that emerged were M184V/I (n&nbsp;=&nbsp;11) and K65R/N (n&nbsp;=&nbsp;2) in RT and T66T/A/I/V (n&nbsp;=&nbsp;2), E92Q (n&nbsp;=&nbsp;4), Q148Q/R (n&nbsp;=&nbsp;1), and N155H (n&nbsp;=&nbsp;2) in integrase. &nbsp;Of the HIV-1 isolates from 12 patients with resistance development in the E/C/F/TDF group, the mutations that emerged were M184V/I (n&nbsp;=&nbsp;9), K65R/N (n&nbsp;=&nbsp;4), and L210W (n = 1) in RT and E92Q/V (n&nbsp;=&nbsp;4) and Q148R (n&nbsp;=&nbsp;2), and N155H/S (n=3) in integrase. &nbsp;Most HIV‑1&nbsp;isolates from patients in both treatment groups who developed resistance mutations to elvitegravir in integrase also developed resistance mutations to emtricitabine in RT.</p><p><em>In patients co‑infected with HIV and HBV</em></p><p>In a clinical study of HIV virologically suppressed patients co‑infected with chronic hepatitis B, who received emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed‑dose combination tablet (E/C/F/TAF), for 48&nbsp;weeks (GS‑US‑292‑1249, n&nbsp;=&nbsp;72), 2&nbsp;patients qualified for resistance analysis.&nbsp; In these 2&nbsp;patients, no amino acid substitutions associated with resistance to any of the components of E/C/F/TAF were identified in HIV‑1 or HBV.</p><p><em>Cross-resistance in HIV‑1&nbsp;infected, treatment-na&iuml;ve or virologically suppressed patients</em></p><p>Emtricitabine-resistant viruses with the M184V/I substitution were cross-resistant to lamivudine, but retained sensitivity to didanosine, stavudine, tenofovir, and zidovudine.</p><p>The K65R and K70E mutations result in reduced susceptibility to abacavir, didanosine, lamivudine, emtricitabine, and tenofovir, but retain sensitivity to zidovudine.</p><p>Multinucleoside-resistant HIV‑1 with a T69S double insertion mutation or with a Q151M mutation complex including K65R showed reduced susceptibility to tenofovir alafenamide.</p><p>&nbsp;</p><p><u>Clinical data</u></p><p>There are no efficacy and safety studies conducted in treatment-na&iuml;ve patients with Descovy.</p><p>Clinical efficacy of Descovy was established from studies conducted with emtricitabine and tenofovir alafenamide when given with elvitegravir and cobicistat as the fixed-dose combination tablet E/C/F/TAF.</p><p><em>HIV‑1&nbsp;infected, treatment-na&iuml;ve patients</em></p><p>In studies GS‑US‑292‑0104 and GS‑US‑292‑0111, patients were randomised in a 1:1&nbsp;ratio to receive either emtricitabine 200&nbsp;mg and tenofovir alafenamide 10&nbsp;mg (n&nbsp;=&nbsp;866) once daily or emtricitabine 200&nbsp;mg&nbsp;+ tenofovir disoproxil (as fumarate) 245&nbsp;mg (n&nbsp;=&nbsp;867) once daily, both given with elvitegravir 150&nbsp;mg&nbsp;+ cobicistat 150&nbsp;mg as a fixed-dose combination tablet. &nbsp;The mean age was 36&nbsp;years (range: 18‑76), 85% were male, 57% were White, 25% were Black, and 10% were Asian. &nbsp;Nineteen percent of patients were identified as Hispanic/Latino. &nbsp;The mean baseline plasma HIV‑1&nbsp;RNA was 4.5&nbsp;log<sub>10</sub>&nbsp;copies/mL (range: 1.3‑7.0) and 23% had baseline viral loads &gt;&nbsp;100,000&nbsp;copies/mL. &nbsp;The mean baseline CD4+&nbsp;cell count was 427&nbsp;cells/mm<sup>3</sup> (range: 0‑1,360) and 13% had a CD4+&nbsp;cell count &lt;&nbsp;200&nbsp;cells/mm<sup>3</sup>.</p><p>E/C/F/TAF demonstrated statistical superiority in achieving HIV‑1&nbsp;RNA &lt;&nbsp;50&nbsp;copies/mL when compared to E/C/F/TDF at Week 144.&nbsp; The difference in percentage was 4.2% (95% CI: 0.6% to 7.8%).&nbsp; Pooled treatment outcomes at 48 and 144&nbsp;weeks are shown in Table&nbsp;4.</p><p><strong>Table&nbsp;4: Pooled virological outcomes of Studies GS‑US‑292‑0104 and GS‑US‑292‑0111 at Weeks 48 and 144<sup>a,b</sup></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Week 48</p></td><td colspan="2" style="vertical-align:top"><p>Week 144</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>E/C/F/TAF</p><p>(n&nbsp;=&nbsp;866)</p></td><td style="vertical-align:top"><p>E/C/F/TDF<sup>e</sup></p><p>(n&nbsp;=&nbsp;867)</p></td><td style="vertical-align:top"><p>E/C/F/TAF</p><p>(n = 866)</p></td><td style="vertical-align:top"><p>E/C/F/TDF</p><p>(n = 867)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>HIV‑1&nbsp;RNA &lt;&nbsp;50&nbsp;copies/mL</p></td><td style="vertical-align:top"><p>92%</p></td><td style="vertical-align:top"><p>90%</p></td><td style="vertical-align:top"><p>84%</p></td><td style="vertical-align:top"><p>80%</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference</p></td><td colspan="2" style="vertical-align:top"><p>2.0% (95% CI: ‑0.7% to 4.7%)</p></td><td colspan="2" style="vertical-align:top"><p>4.2% (95% CI: 0.6% to 7.8%)</p></td></tr><tr><td style="vertical-align:top"><p>HIV‑1&nbsp;RNA &ge;&nbsp;50&nbsp;copies/mL<sup>c</sup></p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>4%</p></td></tr><tr><td style="vertical-align:top"><p>No virologic data at Week&nbsp;48 or 144 window</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>6%</p></td><td style="vertical-align:top"><p>11%</p></td><td style="vertical-align:top"><p>16%</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued study drug due to AE or death<sup>d</sup></p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued study drug due to other reasons and last available HIV‑1&nbsp;RNA &lt;&nbsp;50&nbsp;copies/mL<sup>e</sup></p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>9%</p></td><td style="vertical-align:top"><p>11%</p></td></tr><tr><td style="vertical-align:top"><p>Missing data during window but on study drug</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>&lt;&nbsp;1%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>Proportion (%) of patients with HIV‑1&nbsp;RNA &lt;&nbsp;50&nbsp;copies/mL by subgroup</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Age</p><p>&lt;&nbsp;50&nbsp;years</p><p>&ge;&nbsp;50&nbsp;years</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>716/777 (92%)</p><p>84/89 (94%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>680/753 (90%)</p><p>104/114 (91%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>647/777 (83%) 82/89 (92%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>602/753 (80%) 92/114 (81%)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Sex</p><p>Male</p><p>Female</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>674/733 (92%)</p><p>126/133 (95%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>673/740 (91%)</p><p>111/127 (87%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>616/733 (84%) 113/133 (85%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>603/740 (81%) 91/127 (72%)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Race</p><p>Black</p><p>Non‑black</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>197/223 (88%)</p><p>603/643 (94%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>177/213 (83%)</p><p>607/654 (93%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>168/223 (75%) 561/643 (87%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>152/213 (71%) 542/654 (83%)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline viral load</p><p>&le;&nbsp;100,000&nbsp;copies/mL</p><p>&gt;&nbsp;100,000&nbsp;copies/mL</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>629/670 (94%)</p><p>171/196 (87%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>610/672 (91%)</p><p>174/195 (89%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>567/670 (85%)</p><p>162/196 (83%)&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>537/672 (80%) 157/195 (81%)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline CD4+&nbsp;cell count</p><p>&lt;&nbsp;200&nbsp;cells/mm<sup>3</sup></p><p>&ge;&nbsp;200&nbsp;cells/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>96/112 (86%)</p><p>703/753 (93%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>104/117 (89%)</p><p>680/750 (91%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>93/112 (83%) 635/753 (84%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>94/117 (80%) 600/750 (80%)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>HIV‑1&nbsp;RNA &lt;&nbsp;20&nbsp;copies/mL</p></td><td style="vertical-align:top"><p>84.4%</p></td><td style="vertical-align:top"><p>84.0%</p></td><td style="vertical-align:top"><p>81.1%</p></td><td style="vertical-align:top"><p>75.8%</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference</p></td><td colspan="2" style="vertical-align:top"><p>0.4% (95% CI: ‑3.0% to 3.8%)</p></td><td colspan="2" style="vertical-align:top"><p>5.4% (95% CI: 1.5% to 9.2%)</p></td></tr></tbody></table><p>E/C/F/TAF&nbsp;=&nbsp;elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide</p><p>E/C/F/TDF&nbsp;=&nbsp;elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate</p><p>a&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;48 window was between Day&nbsp;294 and 377 (inclusive); Week 144 window was between Day 966 and 1049 (inclusive).</p><p>b&nbsp;&nbsp;&nbsp; In both studies, patients were stratified by baseline HIV‑1&nbsp;RNA (&le;&nbsp;100,000&nbsp;copies/mL, &gt;&nbsp;100,000&nbsp;copies/mL to &le;&nbsp;400,000&nbsp;copies/mL, or &gt;&nbsp;400,000&nbsp;copies/mL), by CD4+&nbsp;cell count (&lt;&nbsp;50&nbsp;cells/&mu;L, 50‑199&nbsp;cells/&mu;L, or &ge;&nbsp;200&nbsp;cells/&mu;L), and by region (US or ex‑US).</p><p>c&nbsp;&nbsp;&nbsp; Includes patients who had &ge;&nbsp;50&nbsp;copies/mL in the Week&nbsp;48 or 144 window; patients who discontinued early due to lack or loss of efficacy; patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of &ge;&nbsp;50&nbsp;copies/mL.</p><p>d&nbsp;&nbsp;&nbsp; Includes patients who discontinued due to AE or death at any time point from Day&nbsp;1 through the time window if this resulted in no virologic data on treatment during the specified window.</p><p>e&nbsp;&nbsp;&nbsp; Includes patients who discontinued for reasons other than an AE, death or lack or loss of efficacy; e.g., withdrew consent, loss to follow‑up, etc.</p><p>&nbsp;</p><p>The mean increase from baseline in CD4+&nbsp;cell count was 230&nbsp;cells/mm<sup>3</sup> in patients receiving E/C/F/TAF and 211&nbsp;cells/mm<sup>3</sup> in patients receiving E/C/F/TDF (p&nbsp;=&nbsp;0.024) at Week 48, and 326 cells/mm<sup>3</sup> in E/C/F/TAF-treated patients and 305 cells/mm<sup>3</sup> in E/C/F/TDF-treated patients (p = 0.06) at Week 144.</p><p>Clinical efficacy of Descovy in treatment-na&iuml;ve patients was also established from a study conducted with emtricitabine and tenofovir alafenamide (10&nbsp;mg) when given with darunavir (800&nbsp;mg) and cobicistat as a fixed-dose combination tablet (D/C/F/TAF).&nbsp; In Study GS‑US‑299‑0102, patients were randomised in a 2:1&nbsp;ratio to receive either fixed-dose combination D/C/F/TAF once daily (n&nbsp;=&nbsp;103) or darunavir and cobicistat and emtricitabine/tenofovir disoproxil fumarate once daily (n&nbsp;=&nbsp;50).&nbsp; The proportions of patients with plasma HIV‑1&nbsp;RNA &lt;&nbsp;50&nbsp;copies/mL and &lt;&nbsp;20&nbsp;copies/mL are shown in Table&nbsp;5.</p><p><strong>Table&nbsp;5: Virological outcomes of Study GS‑US‑299‑0102 at Week&nbsp;24 and 48<sup>a</sup></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:615px"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Week&nbsp;24</p></td><td colspan="2" style="vertical-align:top"><p>Week&nbsp;48</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>D/C/F/TAF</p><p>(n&nbsp;=&nbsp;103)</p></td><td style="vertical-align:top"><p>Darunavir,</p><p>cobicistat and emtricitabine/tenofovir disoproxil fumarate (n&nbsp;=&nbsp;50)</p></td><td style="vertical-align:top"><p>D/C/F/TAF</p><p>(n&nbsp;=&nbsp;103)</p></td><td style="vertical-align:top"><p>Darunavir,</p><p>cobicistat and emtricitabine/tenofovir disoproxil fumarate (n&nbsp;=&nbsp;50)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>HIV‑1&nbsp;RNA &lt;&nbsp;50&nbsp;copies/mL</p></td><td style="vertical-align:top"><p>75%</p></td><td style="vertical-align:top"><p>74%</p></td><td style="vertical-align:top"><p>77%</p></td><td style="vertical-align:top"><p>84%</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference</p></td><td colspan="2" style="vertical-align:top"><p>3.3% (95% CI: ‑11.4% to 18.1%)</p></td><td colspan="2" style="vertical-align:top"><p>‑6.2% (95% CI: ‑19.9% to 7.4%)</p></td></tr><tr><td style="vertical-align:top"><p>HIV‑1&nbsp;RNA &ge;&nbsp;50&nbsp;copies/mL<sup>b</sup></p></td><td style="vertical-align:top"><p>20%</p></td><td style="vertical-align:top"><p>24%</p></td><td style="vertical-align:top"><p>16%</p></td><td style="vertical-align:top"><p>12%</p></td></tr><tr><td style="vertical-align:top"><p>No virologic data at Week&nbsp;48 window</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>8%</p></td><td style="vertical-align:top"><p>4%</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued study drug due to AE or death<sup>c </sup></p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued study drug due to other reasons and last available HIV‑1&nbsp;RNA &lt;&nbsp;50&nbsp;copies/mL<sup>d</sup></p></td><td><p>4%</p></td><td><p>2%</p></td><td><p>7%</p></td><td><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Missing data during window but on study drug</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>HIV‑1&nbsp;RNA &lt;&nbsp;20&nbsp;copies/mL</p></td><td style="vertical-align:top"><p>55%</p></td><td style="vertical-align:top"><p>62%</p></td><td style="vertical-align:top"><p>63%</p></td><td style="vertical-align:top"><p>76%</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference</p></td><td colspan="2" style="vertical-align:top"><p>‑3.5% (95% CI: ‑19.8% to 12.7%)</p></td><td colspan="2" style="vertical-align:top"><p>‑10.7% (95% CI: ‑26.3% to 4.8%)</p></td></tr></tbody></table><p>D/C/F/TAF&nbsp;=&nbsp;darunavir/cobicistat/emtricitabine/tenofovir alafenamide</p><p>a&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;48 window was between Day&nbsp;294 and 377 (inclusive).</p><p>b&nbsp;&nbsp;&nbsp; Includes patients who had &ge;&nbsp;50&nbsp;copies/mL in the Week&nbsp;48 window; patients who discontinued early due to lack or loss of efficacy; patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of &ge;&nbsp;50&nbsp;copies/mL.</p><p>c&nbsp;&nbsp;&nbsp;&nbsp; Includes patients who discontinued due to AE or death at any time point from Day&nbsp;1 through the time window if this resulted in no virologic data on treatment during the specified window.</p><p>d&nbsp;&nbsp;&nbsp; Includes patients who discontinued for reasons other than an AE, death or lack or loss of efficacy; e.g., withdrew consent, loss to follow‑up, etc.</p><p>&nbsp;</p><p><em>HIV‑1&nbsp;infected virologically suppressed patients</em></p><p>In Study GS‑US‑311‑1089, the efficacy and safety of switching from emtricitabine/tenofovir disoproxil fumarate to Descovy while maintaining the third antiretroviral agent were evaluated in a randomised, double-blind study of virologically suppressed HIV‑1&nbsp;infected adults (n&nbsp;=&nbsp;663).&nbsp; Patients must have been stably suppressed (HIV‑1&nbsp;RNA &lt;&nbsp;50&nbsp;copies/mL) on their baseline regimen for at least 6&nbsp;months and had HIV‑1 with no resistance mutations to emtricitabine or tenofovir alafenamide prior to study entry.&nbsp; Patients were randomised in a 1:1&nbsp;ratio to either switch to Descovy (n&nbsp;=&nbsp;333), or stay on their baseline emtricitabine/tenofovir disoproxil fumarate containing regimen (n&nbsp;=&nbsp;330).&nbsp; Patients were stratified by the class of the third agent in their prior treatment regimen.&nbsp; At baseline, 46% of patients were receiving emtricitabine/tenofovir disoproxil fumarate in combination with a boosted PI and 54% of patients were receiving emtricitabine/tenofovir disoproxil fumarate in combination with an unboosted third agent.</p><p>Treatment outcomes of Study GS‑US‑311‑1089 through 48 and&nbsp;96&nbsp;weeks are presented in Table&nbsp;6.</p><p><strong>Table&nbsp;6: Virological outcomes of Study GS‑US‑311‑1089 at Weeks&nbsp;48<sup>a</sup> and 96<sup>b</sup></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:619px"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Week 48</p></td><td colspan="2" style="vertical-align:top"><p>Week 96</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Descovy containing regimen</p><p>(n&nbsp;=&nbsp;333)</p></td><td style="vertical-align:top"><p>Emtricitabine/tenofovir disoproxil fumarate containing regimen</p><p>(n&nbsp;=&nbsp;330)</p></td><td style="vertical-align:top"><p>Descovy containing regimen</p><p>(n&nbsp;=&nbsp;333)</p></td><td style="vertical-align:top"><p>Emtricitabine/tenofovir disoproxil fumarate containing regimen</p><p>(n&nbsp;=&nbsp;330)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>HIV‑1&nbsp;RNA &lt;&nbsp;50&nbsp;copies/mL</p></td><td style="vertical-align:top"><p>94%</p></td><td style="vertical-align:top"><p>93%</p></td><td style="vertical-align:top"><p>89%</p></td><td style="vertical-align:top"><p>89%</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference</p></td><td colspan="2" style="vertical-align:top"><p>1.3% (95% CI: ‑2.5% to 5.1%)</p></td><td colspan="2" style="vertical-align:top"><p>‑0.5% (95% CI: ‑5.3% to 4.4%)</p></td></tr><tr><td style="vertical-align:top"><p>HIV‑1&nbsp;RNA &ge;&nbsp;50&nbsp;copies/mL<sup>c</sup></p></td><td style="vertical-align:top"><p>&lt;&nbsp;1%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>No virologic data at Week&nbsp;48 or 96 window</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>9%</p></td><td style="vertical-align:top"><p>10%</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued study drug due to AE or death<sup>d</sup></p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued study drug due to other reasons and last available HIV‑1&nbsp;RNA &lt;&nbsp;50&nbsp;copies/mL<sup>e</sup></p></td><td><p>3%</p></td><td><p>5%</p></td><td style="vertical-align:top"><p>7%</p></td><td style="vertical-align:top"><p>9%</p></td></tr><tr><td style="vertical-align:top"><p>Missing data during window but on study drug</p></td><td style="vertical-align:top"><p>&lt;&nbsp;1%</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>&lt;1%</p></td></tr><tr><td style="vertical-align:top"><p>Proportion (%) of patients with HIV‑1&nbsp;RNA &lt;&nbsp;50&nbsp;copies/mL by prior treatment regimen</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Boosted PIs</p></td><td style="vertical-align:top"><p>142/155 (92%)</p></td><td style="vertical-align:top"><p>140/151 (93%)</p></td><td style="vertical-align:top"><p>133/155 (86%)</p></td><td style="vertical-align:top"><p>133/151 (88%)</p></td></tr><tr><td style="vertical-align:top"><p>Other third agents</p></td><td style="vertical-align:top"><p>172/178 (97%)</p></td><td style="vertical-align:top"><p>167/179 (93%)</p></td><td style="vertical-align:top"><p>162/178 (91%)&nbsp;</p></td><td style="vertical-align:top"><p>161/179 (90%)</p></td></tr></tbody></table><p>PI&nbsp;=&nbsp;protease inhibitor</p><p>a&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;48 window was between Day&nbsp;294 and 377 (inclusive).</p><p>b&nbsp;&nbsp;&nbsp; Week&nbsp;96 window was between Day&nbsp;630 and 713 (inclusive).</p><p>c&nbsp;&nbsp;&nbsp;&nbsp; Includes patients who had &ge;&nbsp;50&nbsp;copies/mL in the Week&nbsp;48 or Week 96 window; patients who discontinued early due to lack or loss of efficacy; patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of &ge;&nbsp;50&nbsp;copies/mL.</p><p>d&nbsp;&nbsp;&nbsp; Includes patients who discontinued due to AE or death at any time point from Day&nbsp;1 through the time window if this resulted in no virologic data on treatment during the specified window.</p><p>e&nbsp;&nbsp;&nbsp;&nbsp; Includes patients who discontinued for reasons other than an AE, death or lack or loss of efficacy; e.g., withdrew consent, loss to follow‑up, etc.</p><p>&nbsp;</p><p>In Study GS-US-311-1717, patients who were virologically suppressed (HIV‑1 RNA &lt;50 copies/mL) on their abacavir/lamivudine<strong> </strong>containing regimen for at least 6 months were randomised in a 1:1 ratio to either switch to Descovy (N=280) while maintaining their third agent at baseline or stay on their baseline abacavir/lamivudine -containing regimen (N=276).</p><p>Patients were stratified by the class of the third agent in their prior treatment regimen. At baseline, 30% of patients were receiving abacavir/lamivudine in combination with a boosted protease inhibitor and 70% of patients were receiving abacavir/lamivudine in combination with an unboosted third&nbsp;agent. Virologic success rates at Week 48 were: Descovy Containing Regimen:&nbsp; 89.7% (227 of 253 subjects); Abacavir/lamivudine Containing Regimen: 92.7%% (230 of 248 subjects). At Week 48, switching to a Descovy-containing regimen was non-inferior to staying on a baseline abacavir/lamivudine-containing regimen in maintaining HIV-1 RNA &lt; 50 copies/mL</p><p><em>HIV‑1&nbsp;infected patients with mild to moderate renal impairment</em></p><p>In Study GS‑US‑292‑0112, the efficacy and safety of emtricitabine and tenofovir alafenamide were evaluated in an open-label clinical study in which 242&nbsp;HIV‑1&nbsp;infected patients with mild to moderate renal impairment (eGFR<sub>CG</sub>: 30‑69&nbsp;mL/min) were switched to emtricitabine and tenofovir alafenamide (10&nbsp;mg) given with elvitegravir and cobicistat as a fixed-dose combination tablet. &nbsp;Patients were virologically suppressed (HIV‑1&nbsp;RNA &lt;&nbsp;50&nbsp;copies/mL) for at least 6&nbsp;months before switching.</p><p>The mean age was 58&nbsp;years (range: 24‑82), with 63&nbsp;patients (26%) who were &ge;&nbsp;65&nbsp;years of age. &nbsp;Seventy-nine percent were male, 63% were White, 18% were Black, and 14% were Asian. &nbsp;Thirteen percent of patients were identified as Hispanic/Latino. &nbsp;At baseline, median eGFR was 56&nbsp;mL/min, and 33% of patients had an eGFR from 30 to 49&nbsp;mL/min. &nbsp;The mean baseline CD4+&nbsp;cell count was 664&nbsp;cells/mm<sup>3</sup> (range: 126‑1,813).</p><p>At Week&nbsp;144, 83.1% (197/237&nbsp;patients) maintained HIV‑1&nbsp;RNA &lt;&nbsp;50&nbsp;copies/mL after switching to emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat as a fixed-dose combination tablet. &nbsp;</p><p>In Study GS‑US‑292‑1825, the efficacy and safety of emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed‑dose combination tablet were evaluated in a single arm, open‑label clinical study in which 55&nbsp;HIV‑1 infected adults with end&nbsp;stage renal disease (eGFR<sub>CG</sub>&nbsp;&lt;&nbsp;15&nbsp;mL/min) on chronic haemodialysis for at least 6&nbsp;months before switching to emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed‑dose combination tablet. &nbsp;Patients were virologically suppressed (HIV‑1 RNA&nbsp;&lt;&nbsp;50 copies/mL) for at least 6&nbsp;months before switching.</p><p>The mean age was 48&nbsp;years (range 23‑64). &nbsp;Seventy‑six percent were male, 82% were Black and 18% were White. &nbsp;Fifteen percent of patients identified as Hispanic/Latino. &nbsp;The mean baseline CD4+ cell count was 545&nbsp;cells/mm<sup>3</sup> (range 205‑1473). &nbsp;At Week&nbsp;48, 81.8% (45/55&nbsp;patients) maintained HIV‑1 RNA&nbsp;&lt;&nbsp;50&nbsp;copies/mL after switching to emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed‑dose combination tablet. &nbsp;There were no clinically significant changes in fasting lipid laboratory tests in patients who switched.</p><p><em>Patients co‑infected with HIV and HBV</em></p><p>In open‑label Study GS‑US‑292‑1249, the efficacy and safety of emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet (E/C/F/TAF), were evaluated in adult patients co‑infected with HIV‑1 and chronic hepatitis B.&nbsp; Sixty‑nine of the 72&nbsp;patients were on prior TDF‑containing antiretroviral therapy.&nbsp; At the start of treatment with E/C/F/TAF, the 72&nbsp;patients had been HIV‑suppressed (HIV‑1&nbsp;RNA&nbsp;&lt;&nbsp;50&nbsp;copies/mL) for at least 6&nbsp;months with or without suppression of HBV DNA and had compensated liver function.&nbsp; The mean age was 50&nbsp;years (range 28‑67), 92% of patients were male, 69% were White, 18% were Black, and 10% were Asian.&nbsp; The mean baseline CD4+ cell count was 636&nbsp;cells/mm<sup>3</sup> (range 263‑1498).&nbsp; Eighty‑six&nbsp;percent of patients (62/72) were HBV suppressed (HBV DNA&nbsp;&lt;&nbsp;29&nbsp;IU/mL) and 42% (30/72) were HBeAg positive at baseline.</p><p>Of the patients who were HBeAg positive at baseline, 1/30 (3.3%) achieved seroconversion to anti‑HBe at Week&nbsp;48.&nbsp; Of the patients who were HBsAg positive at baseline, 3/70 (4.3%) achieved seroconversion to anti‑HBs Week&nbsp;48.</p><p>At Week&nbsp;48, 92% of patients (66/72) maintained HIV‑1 RNA&nbsp;&lt;&nbsp;50 copies/mL after switching to emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet.&nbsp; The mean change from baseline in CD4+ cell count at Week&nbsp;48 was ‑2 cells/mm<sup>3</sup>.&nbsp; Ninety‑two&nbsp;percent (66/72 patients) had HBV&nbsp;DNA&nbsp;&lt;&nbsp;29 IU/mL using missing&nbsp;=&nbsp;failure analysis at Week&nbsp;48.&nbsp; Of the 62&nbsp;patients who were HBV suppressed at baseline, 59&nbsp;remained suppressed and 3&nbsp;had missing data. Of the 10&nbsp;patients who were not HBV suppressed at baseline (HBV&nbsp;DNA&nbsp;&ge;&nbsp;29&nbsp;IU/mL), 7&nbsp;became suppressed, 2&nbsp;remained detectable, and 1&nbsp;had missing data.</p><p>There are limited clinical data on the use of E/C/F/TAF in HIV/HBV co‑infected patients who are treatment‑na&iuml;ve.</p><p><em>Changes in measures of bone mineral density</em></p><p>In studies in treatment-na&iuml;ve patients, emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat as a fixed-dose combination tablet was associated with smaller reductions in bone mineral density (BMD) compared to E/C/F/TDF through 144 weeks of treatment as measured by dual energy X&nbsp;ray absorptiometry (DXA) analysis of hip (mean change: &minus;0.8% vs &minus;3.4%, p &lt; 0.001) and lumbar spine (mean change: &minus;0.9% vs &minus;3.0%, p &lt; 0.001). In a separate study, emtricitabine and tenofovir alafenamide given with&nbsp; darunavir and cobicistat as a fixed-dose combination tablet was also associated with smaller reductions in BMD (as measured by hip and lumbar spine DXA analysis) through 48 weeks of treatment compared to darunavir, cobicistat, emtricitabine and tenofovir disoproxil fumarate.&nbsp;</p><p>In a study in virologically suppressed adult patients, improvements in BMD were noted through 96&nbsp;weeks after switching to Descovy from a TDF&nbsp;containing regimen compared to minimal changes with maintaining the TDF&nbsp;containing regimen as measured by DXA analysis of hip (mean change from baseline of 1.9% vs ‑0.3%, p&nbsp;&lt;&nbsp;0.001) and lumbar spine (mean change from baseline of 2.2% vs ‑0.2%, p&nbsp;&lt;&nbsp;0.001).</p><p>In a study in virologically suppressed adult patients, BMD did not change significantly through 48 weeks after switching to Descovy from an abacavir/lamivudine containing regimen compared to maintaining the abacavir/lamivudine containing regimen as measured by DXA analysis of hip (mean change from baseline of 0.3% vs 0.2%, p&nbsp;=&nbsp;0.55) and lumbar spine (mean change from baseline of 0.1% vs &lt;&nbsp;0.1%, p&nbsp;=&nbsp;0.78).</p><p><em>Changes in measures of renal function</em></p><p>In studies in treatment-na&iuml;ve patients, emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat as a fixed-dose combination tablet through 144 weeks was associated with a lower impact on renal safety parameters (as measured after 144 weeks treatment by eGFR<sub>CG</sub> and urine protein to creatinine ratio and after 96 weeks treatment by urine albumin to creatinine ratio) compared to E/C/F/TDF. Through 144 weeks of treatment, no subject discontinued E/C/F/TAF due to a treatment‑emergent renal adverse event compared with 12&nbsp;subjects who discontinued E/C/F/TDF (p&nbsp;&lt;&nbsp;0.001).</p><p>In a separate study in treatment-na&iuml;ve patients, emtricitabine and tenofovir alafenamide given with darunavir and cobicistat as a fixed-dose combination tablet was associated with a lower impact on renal safety parameters through 48 weeks of treatment compared to darunavir and cobicistat given with emtricitabine/tenofovir disoproxil fumarate (see also section&nbsp;4.4).</p><p>In a study in virologically suppressed adult patients measures of tubular proteinuria were similar in patients switching to a regimen containing Descovy compared to patients who stayed on an abacavir/lamivudine containing regimen at baseline. At Week 48, the median percentage change in urine retinol binding protein to creatinine ratio was 4% in the Descovy group and 16% in those remaining on an abacavir/lamivudine containing regimen; and in urine beta-2 microglobulin to creatinine ratio it was 4% vs. 5%.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>In Study GS‑US‑292‑0106, the efficacy, safety, and pharmacokinetics of emtricitabine and tenofovir alafenamide were evaluated in an open-label study in which 50&nbsp;HIV‑1&nbsp;infected, treatment-na&iuml;ve adolescents received emtricitabine and tenofovir alafenamide (10&nbsp;mg) given with elvitegravir and cobicistat as a fixed-dose combination tablet. &nbsp;Patients had a mean age of 15&nbsp;years (range: 12‑17), and 56% were female, 12% were Asian, and 88% were Black. &nbsp;At baseline, median plasma HIV‑1&nbsp;RNA was 4.7&nbsp;log<sub>10</sub>&nbsp;copies/mL, median CD4+&nbsp;cell count was 456&nbsp;cells/mm<sup>3</sup> (range: 95‑1,110), and median CD4+% was 23% (range: 7‑45%). &nbsp;Overall, 22% had baseline plasma HIV‑1&nbsp;RNA &gt;&nbsp;100,000&nbsp;copies/mL.&nbsp; At 48&nbsp;weeks, 92% (46/50) achieved HIV‑1&nbsp;RNA &lt;&nbsp;50&nbsp;copies/mL, similar to response rates in studies of treatment-na&iuml;ve HIV‑1&nbsp;infected adults. &nbsp;The mean increase from baseline in CD4+&nbsp;cell count at Week&nbsp;48 was 224&nbsp;cells/mm<sup>3</sup>. &nbsp;No emergent resistance to E/C/F/TAF was detected through Week&nbsp;48.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Emtricitabine is rapidly and extensively absorbed following oral administration with peak plasma concentrations occurring at 1 to 2&nbsp;hours post-dose.&nbsp; Following multiple dose oral administration of emtricitabine to 20&nbsp;HIV‑1&nbsp;infected subjects, the (mean&nbsp;&plusmn;&nbsp;SD) steady state plasma emtricitabine peak concentrations (C<sub>max</sub>) were 1.8&nbsp;&plusmn;&nbsp;0.7&nbsp;&mu;g/mL and the area‑under the plasma concentration‑time curve over a 24‑hour dosing interval (AUC) was 10.0&nbsp;&plusmn;&nbsp;3.1&nbsp;&mu;g&bull;h/mL.&nbsp; The mean steady state plasma trough concentration at 24&nbsp;hours post-dose was equal to or greater than the mean <em>in&nbsp;vitro</em> IC90 value for anti‑HIV‑1&nbsp;activity.</p><p>Emtricitabine systemic exposure was unaffected when emtricitabine was administered with food.</p><p>Following administration of food in healthy subjects, peak plasma concentrations were observed approximately 1&nbsp;hour post-dose for tenofovir alafenamide administered as F/TAF (25&nbsp;mg) or E/C/F/TAF (10&nbsp;mg).&nbsp; The mean C<sub>max</sub> and AUC<sub>last</sub>, (mean&nbsp;&plusmn;&nbsp;SD) under fed conditions following a single 25&nbsp;mg dose of tenofovir alafenamide administered in Descovy were 0.21&nbsp;&plusmn;&nbsp;0.13&nbsp;&mu;g/mL and 0.25&nbsp;&plusmn;&nbsp;0.11&nbsp;&mu;g&bull;h/mL, respectively.&nbsp; The mean C<sub>max</sub> and AUC<sub>last</sub> following a single 10&nbsp;mg dose of tenofovir alafenamide administered in E/C/F/TAF were 0.21&nbsp;&plusmn;&nbsp;0.10&nbsp;&mu;g/mL and 0.25&nbsp;&plusmn;&nbsp;0.08&nbsp;&mu;g&bull;h/mL, respectively.</p><p>Relative to fasting conditions, the administration of tenofovir alafenamide with a high fat meal (~800&nbsp;kcal, 50% fat) resulted in a decrease in tenofovir alafenamide C<sub>max</sub> (15‑37%) and an increase in AUC<sub>last</sub> (17‑77%).</p><p><u>Distribution</u></p><p><em>In&nbsp;vitro</em> binding of emtricitabine to human plasma proteins was &lt;&nbsp;4% and independent of concentration over the range of 0.02‑200&nbsp;&mu;g/mL. &nbsp;At peak plasma concentration, the mean plasma to blood drug concentration ratio was ~1.0 and the mean semen to plasma drug concentration ratio was&nbsp;~4.0.</p><p><em>In&nbsp;vitro</em> binding of tenofovir to human plasma proteins is &lt;&nbsp;0.7% and is independent of concentration over the range of 0.01‑25&nbsp;&mu;g/mL. &nbsp;<em>Ex&nbsp;vivo</em> binding of tenofovir alafenamide to human plasma proteins in samples collected during clinical studies was approximately 80%.</p><p><u>Biotransformation</u></p><p><em>In&nbsp;vitro</em> studies indicate that emtricitabine is not an inhibitor of human CYP&nbsp;enzymes. &nbsp;Following administration of [<sup>14</sup>C]‑emtricitabine, complete recovery of the emtricitabine dose was achieved in urine (~86%) and faeces (~14%). &nbsp;Thirteen percent of the dose was recovered in the urine as three putative metabolites. &nbsp;The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3&rsquo;‑sulfoxide diastereomers (~9% of dose) and conjugation with glucuronic acid to form 2&rsquo;‑O‑glucuronide (~4% of dose). &nbsp;No other metabolites were identifiable.</p><p>Metabolism is a major elimination pathway for tenofovir alafenamide in humans, accounting for &gt;&nbsp;80% of an oral dose. &nbsp;<em>In&nbsp;vitro</em> studies have shown that tenofovir alafenamide is metabolised to tenofovir (major metabolite) by cathepsin&nbsp;A in PBMCs (including lymphocytes and other HIV&nbsp;target cells) and macrophages; and by carboxylesterase‑1 in hepatocytes. &nbsp;<em>In&nbsp;vivo</em>, tenofovir alafenamide is hydrolysed within cells to form tenofovir (major metabolite), which is phosphorylated to the active metabolite tenofovir diphosphate. &nbsp;In human clinical studies, a 10&nbsp;mg oral dose of tenofovir alafenamide (given with emtricitabine and elvitegravir and cobicistat) resulted in tenofovir diphosphate concentrations &gt;&nbsp;4‑fold higher in PBMCs and &gt;&nbsp;90% lower concentrations of tenofovir in plasma as compared to a 245&nbsp;mg oral dose of tenofovir disoproxil (as fumarate) (given with emtricitabine and elvitegravir and cobicistat).</p><p><em>In&nbsp;vitro</em>, tenofovir alafenamide is not metabolised by CYP1A2, CYP2C8, CYP2C9, CYP2C19, or CYP2D6. &nbsp;Tenofovir alafenamide is minimally metabolised by CYP3A4. &nbsp;Upon co‑administration with the moderate CYP3A&nbsp;inducer probe efavirenz, tenofovir alafenamide exposure was not significantly affected. &nbsp;Following administration of tenofovir alafenamide, plasma [<sup>14</sup>C]‑radioactivity showed a time-dependent profile with tenofovir alafenamide as the most abundant species in the initial few hours and uric acid in the remaining period.</p><p><u>Elimination</u></p><p>Emtricitabine is primarily excreted by the kidneys with complete recovery of the dose achieved in urine (approximately&nbsp;86%) and faeces (approximately&nbsp;14%). &nbsp;Thirteen percent of the emtricitabine dose was recovered in urine as three metabolites. &nbsp;The systemic clearance of emtricitabine averaged 307&nbsp;mL/min. &nbsp;Following oral administration, the elimination half‑life of emtricitabine is approximately 10&nbsp;hours.</p><p>Renal excretion of intact tenofovir alafenamide is a minor pathway with &lt;&nbsp;1% of the dose eliminated in urine. &nbsp;Tenofovir alafenamide is mainly eliminated following metabolism to tenofovir.&nbsp; Tenofovir alafenamide and tenofovir have a median plasma half-life of 0.51 and 32.37&nbsp;hours, respectively.&nbsp; Tenofovir is renally eliminated by both glomerular filtration and active tubular secretion.</p><p><u>Pharmacokinetics in special populations</u></p><p><em>Age, gender, and ethnicity</em></p><p>No clinically relevant pharmacokinetic differences due to age, gender or ethnicity have been identified for emtricitabine, or tenofovir alafenamide.</p><p><u>Paediatric population</u></p><p>Exposures of emtricitabine and tenofovir alafenamide (given with elvitegravir and cobicistat) achieved in 24&nbsp;paediatric patients aged 12 to &lt;&nbsp;18&nbsp;years who received emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat in Study GS‑US‑292‑0106 were similar to exposures achieved in treatment-na&iuml;ve adults (Table&nbsp;7).</p><p><strong>Table&nbsp;7: Pharmacokinetics of emtricitabine and tenofovir alafenamide in antiretroviral‑na&iuml;ve adolescents and adults</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>Adolescents</p></td><td colspan="3" style="vertical-align:top"><p>Adults</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>FTC<sup>a</sup></p></td><td><p>TAF<sup>b</sup></p></td><td style="vertical-align:top"><p>TFV<sup>b</sup></p></td><td><p>FTC<sup>a</sup></p></td><td><p>TAF<sup>c</sup></p></td><td style="vertical-align:top"><p>TFV<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>tau</sub> (ng&bull;h/mL)</p></td><td><p>14,424.4 (23.9)</p></td><td><p>242.8 (57.8)</p></td><td style="vertical-align:top"><p>275.8 (18.4)</p></td><td><p>11,714.1 (16.6)</p></td><td><p>206.4 (71.8)</p></td><td style="vertical-align:top"><p>292.6 (27.4)</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> (ng/mL)</p></td><td><p>2,265.0 (22.5)</p></td><td><p>121.7 (46.2)</p></td><td style="vertical-align:top"><p>14.6 (20.0)</p></td><td><p>2,056.3 (20.2)</p></td><td><p>162.2 (51.1)</p></td><td style="vertical-align:top"><p>15.2 (26.1)</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>tau</sub> (ng/mL)</p></td><td><p>102.4 (38.9)<sup>b</sup></p></td><td><p>N/A</p></td><td style="vertical-align:top"><p>10.0 (19.6)</p></td><td><p>95.2 (46.7)</p></td><td><p>N/A</p></td><td style="vertical-align:top"><p>10.6 (28.5)</p></td></tr></tbody></table><p>E/C/F/TAF&nbsp;=&nbsp;elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate</p><p>FTC&nbsp;=&nbsp;emtricitabine; TAF&nbsp;=&nbsp;tenofovir alafenamide fumarate; TFV&nbsp;=&nbsp;tenofovir</p><p>N/A&nbsp;=&nbsp;not applicable</p><p>Data are presented as mean (%CV).</p><p>a&nbsp;&nbsp;&nbsp;&nbsp; n&nbsp;=&nbsp;24&nbsp;adolescents (GS‑US‑292‑0106); n&nbsp;=&nbsp;19&nbsp;adults (GS‑US‑292‑0102)</p><p>b&nbsp;&nbsp;&nbsp; n&nbsp;=&nbsp;23&nbsp;adolescents (GS‑US‑292‑0106, population PK analysis)</p><p>c&nbsp;&nbsp;&nbsp;&nbsp; n&nbsp;=&nbsp;539 (TAF) or 841 (TFV) adults (GS‑US‑292‑0111 and GS‑US‑292‑0104, population PK analysis)</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No clinically relevant differences in tenofovir alafenamide, or tenofovir pharmacokinetics were observed between healthy subjects and patients with severe renal impairment (estimated CrCl &ge;&nbsp;15 mL/min and &lt;&nbsp;30&nbsp;mL/min) in a Phase 1 study of tenofovir alafenamide.&nbsp; In a separate Phase 1 study of emtricitabine alone, mean systemic emtricitabine exposure was higher in patients with severe renal impairment (estimated CrCl&nbsp;&lt;&nbsp;30&nbsp;mL/min) (33.7&nbsp;&mu;g&bull;h/mL) than in subjects with normal renal function (11.8&nbsp;&mu;g&bull;h/mL). The safety of emtricitabine and tenofovir alafenamide has not been established in patients with severe renal impairment (estimated CrCl&nbsp;&ge;&nbsp;15&nbsp;mL/min and &lt;&nbsp;30&nbsp;mL/min).</p><p>Exposures of emtricitabine and tenofovir in 12&nbsp;patients with end&nbsp;stage renal disease (estimated CrCl&nbsp;&lt;&nbsp;15&nbsp;mL/min) on chronic haemodialysis who received emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed‑dose combination tablet (E/C/F/TAF) in Study GS‑US‑292‑1825 were significantly higher than in patients with normal renal function. &nbsp;No clinically relevant differences in tenofovir alafenamide pharmacokinetics were observed in patients with end&nbsp;stage renal disease on chronic haemodialysis as compared to those with normal renal function. &nbsp;There were no new safety issues identified in patients with end&nbsp;stage renal disease on chronic haemodialysis receiving emtricitabine and tenofovir alafenamide, in combination with elvitegravir and cobicistat as a fixed‑dose combination tablet (see section&nbsp;4.8).</p><p>There are no pharmacokinetic data on emtricitabine or tenofovir alafenamide in patients with end&nbsp;stage renal disease (estimated CrCl&nbsp;&lt;&nbsp;15&nbsp;mL/min) not on chronic haemodialysis.&nbsp; The safety of emtricitabine and tenofovir alafenamide has not been established in these patients.</p><p><em>Hepatic impairment</em></p><p>The pharmacokinetics of emtricitabine have not been studied in subjects with hepatic impairment; however, emtricitabine is not significantly metabolised by liver enzymes, so the impact of liver impairment should be limited. &nbsp;</p><p>Clinically relevant changes in the pharmacokinetics of tenofovir alafenamide or its metabolite tenofovir were not observed in patients with mild or moderate hepatic impairment.&nbsp; In patients with severe hepatic impairment, total plasma concentrations of tenofovir alafenamide and tenofovir are lower than those seen in subjects with normal hepatic function. &nbsp;When corrected for protein binding, unbound (free) plasma concentrations of tenofovir alafenamide in severe hepatic impairment and normal hepatic function are similar.</p><p><em>Hepatitis&nbsp;B and/or hepatitis&nbsp;C virus co‑infection</em></p><p>The pharmacokinetics of emtricitabine and tenofovir alafenamide have not been fully evaluated in patients co‑infected with HBV and/or&nbsp;HCV.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data on emtricitabine reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.&nbsp; Emtricitabine has demonstrated low carcinogenic potential in mice and rats.</p><p>Non-clinical studies of tenofovir alafenamide in rats and dogs revealed bone and kidney as the primary target organs of toxicity. &nbsp;Bone toxicity was observed as reduced BMD in rats and dogs at tenofovir exposures at least four times greater than those expected after administration of Descovy.&nbsp; A minimal infiltration of histiocytes was present in the eye in dogs at tenofovir alafenamide and tenofovir exposures of approximately 4 and 17&nbsp;times greater, respectively, than those expected after administration of Descovy.</p><p>Tenofovir alafenamide was not mutagenic or clastogenic in conventional genotoxicity assays.</p><p>Because there is a lower tenofovir exposure in rats and mice after the administration of tenofovir alafenamide compared to tenofovir disoproxil fumarate, carcinogenicity studies and a rat peri-postnatal study were conducted only with tenofovir disoproxil fumarate. &nbsp;No special hazard for humans was revealed in conventional studies of carcinogenic potential and toxicity to reproduction and development. &nbsp;Reproductive toxicity studies in rats and rabbits showed no effects on mating, fertility, pregnancy or foetal parameters. &nbsp;However, tenofovir disoproxil fumarate reduced the viability index and weight of pups in a peri-postnatal toxicity study at maternally toxic doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>Microcrystalline cellulose</p><p>Croscarmellose sodium</p><p>Magnesium stearate</p><p><u>Film‑coating</u></p><p>Polyvinyl alcohol</p><p>Titanium dioxide</p><p>Macrogol 3350</p><p>Talc</p><p>Iron oxide black (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package in order to protect from moisture. &nbsp;Keep the bottle tightly closed.</p><p>Do not store above 30<sup>o</sup>C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>High density polyethylene (HDPE) bottle with a polypropylene continuous-thread, child‑resistant cap, lined with an induction activated aluminium foil liner containing 30&nbsp;film‑coated tablets.&nbsp; Each bottle contains silica gel desiccant and polyester coil.</p><p>&nbsp;</p><p>The following pack size is available: outer cartons containing 1&nbsp;bottle of 30&nbsp;film‑coated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gilead Sciences Ireland UC
IDA Business & Technology Park
Carrigtohill
County Cork
Ireland 
Tel: +353 (0) 21 483 5500
Fax: +353 (0) 21 483 5518
Email: csafety@gilead.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>